var docs;if (!docs) docs =[]; docs["87"]={"8706":"<p><b>Title</b> Alcohol (Ethyl) / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dapoxetine may enhance the adverse/toxic effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients not to use dapoxetine together with alcohol.</p> \n<p><b>Discussion</b> Concurrent administration of a single dose of alcohol (0.5 mg/kg; equivalent to approximately 2 drinks) was not associated with any significant changes in dapoxetine pharmacokinetics.<sup>1,2,3</sup> According to the dapoxetine summary of product characteristics, pharmacodynamic measures indicated additive adverse cognitive effects. As a result, the summary of product characteristics cautions that dapoxetine may increase the likelihood for and/or severity of adverse neurocognitive effects of alcohol (e.g., dizziness, drowsiness, altered judgment, impaired reflexes, etc.) as well as the risk of adverse neurocardiovascular effects such as syncope.<sup>1,2</sup> However, a published study found only non-significant increases in cognitive effects of the combination as compared to ethanol alone (though there were additive effects vs. dapoxetine alone on many parameters).<sup>3</sup><br><br>The specific mechanism for this purported interaction is likely additive central nervous system effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p>3. Modi NB, Dresser M, Desai D, Edgar C, Wesnes K. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. <i>J Clin Pharmacol</i>. 2007;47(3):315-322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17322143\">[PubMed 17322143]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8707":"<p><b>Title</b> Dapoxetine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, grapefruit juice (250 mL daily x 3 days) increased the dapoxetine (60 mg single dose) AUC and maximum serum concentration (Cmax) 60% and 80%, respectively.<sup>1</sup> The AUC and Cmax of dapoxetine were an average of 99% and 35% higher, respectively, with concomitant use of the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day for 7 days) among subjects receiving single doses of dapoxetine (60 mg).<sup>2,3</sup> According to the dapoxetine summary of product characteristics, these changes may be even larger when considering both dapoxetine and its active desmethyldapoxetine metabolite.<sup>2,3</sup><br><br>Dapoxetine product labeling states that the dapoxetine dose should be limited to 30 mg daily when used with moderate CYP3A4 inhibitors.<sup>2,3</sup><br><br>The specific mechanism for this apparent interaction is likely inhibition of the CYP3A4-mediated metabolism of dapoxetine, which is primarily metabolized by CYP3A4 and CYP2D6, leading to increased dapoxetine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abdlekawy KS, Donia AM, Elbarbry F. Effects of grapefruit juice and pomegranate juice on the pharmacokinetic properties of dapoxetine and midazolam in healthy subjects. <i>Eur J Drug Metab Pharmacokinet</i>. 2017;42(3):397-405. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27294349\">[PubMed 27294349]</a></p>\n<p>2. Priligy (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>3. Priligy (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8708":"<p><b>Title</b> Dapoxetine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of dapoxetine together with a strong inhibitor of CYP3A4 is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The AUC and maximum serum concentration (Cmax) of dapoxetine were an average of 99% and 35% higher, respectively, with concomitant use of the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day for 7 days) among subjects receiving single doses of dapoxetine (60 mg).<sup>1,2</sup> According to the dapoxetine summary of product characteristics, these changes may be even larger when considering both dapoxetine and its active desmethyldapoxetine metabolite.<br><br>The specific mechanism for this apparent interaction is likely inhibition of the CYP3A4-mediated metabolism of dapoxetine, which is primarily metabolized by CYP3A4 and CYP2D6, leading to increased dapoxetine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8709":"<p><b>Title</b> Serotonin Modulators / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dapoxetine may enhance the adverse/toxic effect of Serotonin Modulators. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of dapoxetine with medications or natural products that have serotoninergic effects (i.e., serotonin modulators), or within 14 days of discontinuing a serotonin modulator, is contraindicated. Similarly, serotonin modulators should not be used within 7 days of discontinuing dapoxetine.</p>\n<div>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> The concomitant use of 2 or more of agents with serotonergic activity may increase the risk of toxic effects due to central serotonergic overstimulation. These toxic effects may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>1,2</sup> Due to the risk for such toxicities the summary of product characteristics for dapoxetine, a selective serotonin reuptake inhibitor, has contraindicated use with any other serotonergic agent.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>2. Sternbach H. The serotonin syndrome. <i>Am J Psychiatry</i>. 1991;148(6):705-713. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>3. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>4. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8710":"<p><b>Title</b> Thioridazine / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dapoxetine may enhance the arrhythmogenic effect of Thioridazine. Dapoxetine may increase the serum concentration of Thioridazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of dapoxetine with thioridazine, or within 14 days of discontinuing thioridazine, is contraindicated. Similarly,thioridazine should not be used within 7 days of discontinuing dapoxetine.</p> \n<p><b>Discussion</b> According to the summary of product characteristics for dapoxetine concomitant use with thioridazine is contraindicated.<sup>1,2</sup> The reason for this contraindication appears to be concern that dapoxetine may inhibit the CYP2D6-mediated metabolism of thioridazine, increasing thioridazine concentrations and the risk for thioridazine-related prolongation of the QTc interval and associated arrhythmias.<sup>1,2</sup> The extent to which dapoxetine would be expected to inhibit thioridazine metabolism is uncertain, however, as exposure to desipramine (a CYP2D6 substrate, as is thioridazine) was increased by only 19% with concurrent dapoxetine (60 mg/day for 6 days) according to data in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8711":"<p><b>Title</b> Phosphodiesterase 5 Inhibitors / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Dapoxetine should not be used in patients who are taking phosphodiesterase 5 (PDE5) inhibitors due to a possible increased risk for orthostatic hypotension.</p>\n<div>\n <p><b>Phosphodiesterase 5 Inhibitors Interacting Members</b> Avanafil, Mirodenafil, Sildenafil, Tadalafil, Udenafil, Vardenafil</p>\n</div> \n<p><b>Discussion</b> The dapoxetine AUC was an average of 22% higher with concurrent sildenafil in a study of 22 subjects who each received dapoxetine 60 mg alone, dapoxetine 60 mg plus sildenafil 100 mg, and dapoxetine 60 mg plus tadalafil 20 mg.<sup>1</sup> Dapoxetine concentrations were not significantly different with concurrent tadalafil. Blood pressure and heart rate were not significantly altered with use of the combinations, but the incidence of nausea was greater with the combinations (22% to 26% vs. 9%).<sup>1</sup> However, the summary of product characteristics cautions that dapoxetine should not be used by patients who are taking phosphodiesterase 5 (PDE5) inhibitors due to a possible increase in the risk for orthostatic hypotension.<sup>2,3</sup> Orthostatic hypotension has been associated with both dapoxetine and the PDE5 inhibitors, but the specific risk with the combination is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. <i>Int J Impot Res</i>. 2006;18(1):104-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16307008\">[PubMed 16307008]</a></p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>3. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8712":"<p><b>Title</b> Desipramine / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Dapoxetine may increase the serum concentration of Desipramine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Exposure to desipramine was increased by an average of 19% with concurrent dapoxetine (60 mg/day for 6 days) according to data in the dapoxetine summary of product characteristics.<sup>1,2</sup> This change is unlikely to be of substantial clinical significance.<br><br>The mechanism for this interaction is uncertain but may be dapoxetine inhibition of the CYP2D6-mediated metabolism of desipramine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8714":"<p><b>Title</b> Pirfenidone / Ciprofloxacin (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The management and significance of this interaction vary depending on whether the ciprofloxacin daily dose is greater than or equal to 1,500 mg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Pirfenidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible, concomitant use of ciprofloxacin (particularly at higher doses) and pirfenidone should be avoided. If concomitant use cannot be avoided, when using a total daily dose of ciprofloxacin 1,500 mg (750 mg twice daily) the pirfenidone dose should be reduced to 1,602 mg daily (ie, 534 mg three times a day). When using lower doses of ciprofloxacin, no dose adjustment is recommended, but patients should be monitored for increased pirfenidone effects/toxicities.</p> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers described in the pirfenidone prescribing information, ciprofloxacin (750 mg twice daily for 6 days) increased the pirfenidone (801 mg single dose given on day 5) AUC 81%.<sup>1</sup> <br><br>Pirfenidone is primarily metabolized by CYP1A2, with minor contributions from other enzymes, including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> Due to these factors, pirfenidone product labeling recommends use of reduced pirfenidone doses and/or close clinical monitoring when used with drugs that are selective inhibitors of CYP1A2, such as ciprofloxacin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8715":"<p><b>Title</b> Lacosamide / Bradycardia-Causing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased heart rate, heart block and/or prolonged PR interval in patients using lacosamide together with any drugs capable of prolonging the PR interval. If such combinations are used, it is recommended that an electrocardiogram is obtained both prior to use and after reaching the lacosamide maintenance dose. Any such combined use should be done with caution, and patients using intravenous lacosamide and those with severe cardiac disease may be at greater risk.</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to the prescribing information, in vitro studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, which can lead to ECG changes, specifically prolonged PR interval. Many bradycardia-causing drugs exert their affect in the AV node causing prolonged PR interval, which can ultimately lead to bradycardia and/or AV block.<sup>1</sup> The extent of AV block and bradycardia may vary among these agents according to their individual propensity to inhibit AV nodal activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Vimpat</i> (lacosamide) [prescribing information]. Smyrna, GA: UCB, Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8716":"<p><b>Title</b> MetroNIDAZOLE (Systemic) / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of MetroNIDAZOLE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased efficacy and/or treatment failures of metronidazole if used concomitantly with primidone.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 4 healthy volunteers, administration of phenobarbital (the major active metabolite of primidone) 100 mg daily for 7 days increased metronidazole (500 mg single intravenous dose) clearance by 57% and decreased the half-life by 33%.<sup>1</sup> In another study conducted in 6 patients with Crohn's disease, the AUC of metronidazole (250 mg orally twice daily) was decreased by 29% and the AUC of the 2-hydroxy-metronidazole metabolite was increased by 29% when given with phenobarbital (60 mg twice daily).<sup>2</sup> Therapeutic failures of metronidazole have been reported in patients receiving phenobarbital.<sup>3,4</sup> In one case, vaginal trichomoniasis in a woman taking phenobarbital did not respond to treatment until the dose of metronidazole was increased.<sup>3</sup> A pharmacokinetic analysis revealed a metronidazole half-life of 3.5 hours (normal 8 to 9 hours).<sup>3</sup> In another report, 80% of metronidazole treatment failures in a pediatric clinic were found to be in patients also receiving concomitant phenobarbital.<sup>4</sup> An analysis of 15 subsequent children receiving phenobarbital and metronidazole revealed a shortened metronidazole half-life of 3.5 hours.<sup>4</sup> <br><br>As a result, metronidazole prescribing information cautions that phenobarbital may decrease metronidazole concentrations via increased elimination.<sup>5</sup><br><br>The likely mechanism of this interaction is phenobarbital induction of CYP enzymes (likely primarily CYP2A6) responsible for metronidazole metabolism.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. <i>Eur J Clin Pharmacol</i>. 1987;32(1):35-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3582467\">[PubMed 3582467]</a></p>\n<p>2. Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. <i>Biopharm Drug Dispos</i>. 1988;9(2):219-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2897213\">[PubMed 2897213]</a></p>\n<p>3. Mead PB, Gibson M, Schentag JJ, Ziemniak JA. Possible alteration of metronidazole by phenobarbital. <i>N Engl J Med</i>. 1982;306(24):1490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7078600\">[PubMed 7078600]</a></p>\n<p>4. Gupte S. Phenobarbital and metabolism of metronidazole. <i>N Engl J Med</i>. 1983;308(9):529. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6823276\">[PubMed 6823276]</a></p>\n<p>5. <i>Flagyl</i> (metronidazole) [prescribing information]. New York, NY: Pfizer Inc; June 2013.</p>\n<p>6. Rodriguez-Antona C, Jover R, Gomez-Lechon MJ, Castell JV. Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. <i>Arch Biochem Biophys</i>. 2000;376(1):109-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10729196\">[PubMed 10729196]</a></p>\n<p>7. Pearce RE, Cohen-Wolkowiez M, Sampson MR, Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. <i>Drug Metab Dispos</i>. 2013;41(9):1686-1694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23813797\">[PubMed 23813797]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8717":"<p><b>Title</b> Antianxiety Agents / Yohimbine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Yohimbine may diminish the therapeutic effect of Antianxiety Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to antianxiety medications closely when being used with yohimbine.</p>\n<div>\n <p><b>Antianxiety Agents Interacting Members</b> ALPRAZolam, Bromazepam, BusPIRone, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Meprobamate, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n</div> \n<p><b>Discussion</b> Several studies in patients with depression, generalized anxiety, or panic disorders have demonstrated that yohimbine can increase feelings of nervousness, anxiety, and panic, along with increases in blood pressure, as summarized in a review of yohimbine.<sup>1</sup> Of note, patients with panic disorder appear to be particularly sensitive to these effects, as compared to healthy controls.<sup>1</sup> These effects of yohimbine raise concern of a potential interaction between anti-anxiety medications and yohimbine.<br><br>Few data concerning this possible interaction exist. In a study of 16 healthy volunteers the subjective feelings of panic and increase in blood pressure were not ameliorated with diazepam, but were antagonized with the alpha-2 agonist clonidine.<sup>2</sup> Similarly, yohimbine antagonized the effects of alprazolam on subjective ratings of dorwsiness and mellowness as well as the effects on blood pressure and cortisol in a study of 8 healthy volunteers.<sup>3</sup> Though diazepam pretreatment did reduce yohimbine-associated anxiety, only clonidine diminished both anxiety and blood pressure in a study of 10 healthy volunteers.<sup>4</sup><br><br>The specific mechanism by which yohimbine increases feelings of nervousness, anxiety, and panic are uncertain, but evidence that at least some of these effects are responsive to alpha-2 agonists (e.g., clonidine) and resistant to anti-anxiety medications (e.g., benzodiazepines) suggest the mechanism is related to yohimbine's antagonism of the alpha-2 receptor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tam SW, Worcel M,Wyllie M, “Yohimbine: A Clinical Review,” <i>Pharmacol Ther</i>, 2001, 91:215-43.</p>\n<p>2. Mattila M, Seppala T,Mattila MJ, “Anxiogenic Effect of Yohimbine in Healthy Subjects: Comparison with Caffeine and Antagonism by Clonidine and Diazepam,” <i>Int Clin Psychopharmacol</i>, 1988, 3:215-29.</p>\n<p>3. Charney DS, Breier A, Jatlow PI, et al, “Behavioral, Biochemical, and Blood Pressure Responses to Alprazolam in Healthy Subjects: Interactions with Yohimbine,” <i>Psychopharmacology (Berl)</i>, 1986, 88:133-40.</p>\n<p>4. Charney DS, Heninger GR,Redmond DE, Jr., “Yohimbine Induced Anxiety and Increased Noradrenergic Function in Humans: Effects of Diazepam and Clonidine,” <i>Life Sci</i>, 1983, 33:19-29.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8718":"<p><b>Title</b> Alpha1-Blockers / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Alpha1-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as alpha adrenergic receptor antagonists and nitrates) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p>\n<div>\n <p><b>Alpha1-Blockers Interacting Members</b> Alfuzosin, Doxazosin, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin, Silodosin, Tamsulosin, Terazosin</p>\n</div> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as alpha adrenergic receptor antagonists and nitrates) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8719":"<p><b>Title</b> Vasodilators (Organic Nitrates) / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as alpha adrenergic receptor antagonists and nitrates) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p>\n<div>\n <p><b>Vasodilators (Organic Nitrates) Interacting Members</b> Isosorbide Dinitrate, Isosorbide Mononitrate, Nicorandil, Nitroglycerin</p>\n</div> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as alpha adrenergic receptor antagonists and nitrates) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8720":"<p><b>Title</b> OCT2 Substrates / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may increase the serum concentration of OCT2 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for evidence of adverse reactions to OCT2 substrates during concomitant treatment with bupropion.</p>\n<div>\n <p><b>OCT2 Substrates Interacting Members</b> Amantadine, AMILoride, Cimetidine, DOPamine, Famotidine, Memantine, MetFORMIN, Oxaliplatin, Pindolol, Procainamide, RaNITIdine, Varenicline</p>\n</div> \n<p><b>Discussion</b> US prescribing information for a bupropion/naltrexone product recommends cautious use in combination with OCT2 substrates, with monitoring for adverse effects, because bupropion and its metabolites may inhibit OCT2 mediated renal excretion of these drugs.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Contrave</i> (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8722":"<p><b>Title</b> Levobupivacaine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for levobupivacaine toxicity if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> No clinical studies have been conducted with levobupivacaine and CYP3A4 inhibitors. However, <i>in vitro</i> studies indicate that CYP3A4 mediates (at least in part) the metabolism of levobupivacaine.<sup>1,2</sup> Product labeling warns that levobupivacaine metabolism may be reduced in the presence of CYP3A4 inhibitors and that elevated serum concentrations of levobupivacaine could result in toxicity.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Chirocaine</i> (levobupivacaine) [summary of product characteristics]. Maidenhead, Berkshire, United Kingdom: Abbvie Limited; April 2013.</p>\n<p>2. <i>Chirocaine</i> (levobupivacaine) [summary of product characteristics]. Botany, New South Wales, Australia: Abbvie Pty Ltd; December 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8723":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as ACE inhibitors) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as ACE inhibitors) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8724":"<p><b>Title</b> Angiotensin II Receptor Blockers / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as angiotensin II antagonists) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as angiotensin II antagonists) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8725":"<p><b>Title</b> Calcium Channel Blockers / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as calcium channel blockers) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n</div> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as calcium channel blockers) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8726":"<p><b>Title</b> HydrALAZINE / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of HydrALAZINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as hydralazine) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as hydralazine) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8727":"<p><b>Title</b> Minoxidil (Systemic) / Dapoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dapoxetine may enhance the orthostatic hypotensive effect of Minoxidil (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use dapoxetine with caution in patients taking medications with vasodilatation properties (such as minoxidil) due to a possible increase in the risk for orthostatic hypotension and related adverse effects.</p> \n<p><b>Discussion</b> The summary of product characteristics for dapoxetine warns that dapoxetine should be used with caution in patients taking medications with vasodilatation properties (such as minoxidil) due to possibly reduced orthostatic tolerance.<sup>1,2</sup><br><br>Orthostatic hypotension, syncope, and related adverse effects have been reported with dapoxetine in clinical trials, though these are generally characterized as uncommon in the summary of product characteristics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; December 2013.</p>\n<p>2. <i>Priligy</i> (dapoxetine) [summary of product characteristics]. Mapletree Business City, Singapore: A. Menarini Singapore Pte. Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8728":"<p><b>Title</b> Erlotinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of erlotinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, the erlotinib prescribing information recommends increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The erlotinib AUC was reduced by an average of 67% to 81% with concomitant administration of rifampin (600 mg/day for 7 to 11 days), a strong CYP3A4 inducer, in two separate studies in healthy volunteers.<sup>1</sup> Similarly, an in vitro study conducted in cultured hepatocytes found that clearance of erlotinib was increased approximately 2-fold by rifampin and the moderate CYP3A4 inducer efavirenz.<sup>2</sup> As a result of this apparent interaction, the erlotinib prescribing information recommends avoiding this combination when possible, and when the combination must be used, increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.<sup>3</sup><br><br>The likely mechanism for this interaction is increased CYP3A-mediated metabolism of erlotinib, as erlotinib metabolism is primarily mediated by CYP3A4 with some additional contribution by CYP1A2.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2014;73(3):613-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24474302\">[PubMed 24474302]</a></p>\n<p>2. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metab Dispos</i>. 2013;41(10):1843-1851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23913028\">[PubMed 23913028]</a></p>\n<p>3. <i>Tarceva</i> (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals, LLC; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8729":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Diclofenac (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Diclofenac (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory drugs (NSAIDs). Avoid the use of diclofenac/misoprostol with other NSAIDs.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> US prescribing information for at least one diclofenac-containing product recommends that its use be avoided in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 specific inhibitors.<sup>1</sup> Combined use of multiple NSAIDs is expected to increase the risk of some adverse effects, including gastrointestinal adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Arthrotec</i> (diclofenac/misoprostol) [prescribing information]. New York, NY: Pfizer Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8730":"<p><b>Title</b> Erlotinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of severe adverse reactions (e.g., severe diarrhea, severe skin reactions, etc.). If severe adverse reactions do occur, reduce the erlotinib dose (in 50 mg decrements).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The erlotinib AUC and maximum serum concentration (Cmax) were increased by an average of 1.7- and 1.5-fold, respectively, with concomitant administration of the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day for 5 days) in a study of 12 healthy volunteers.<sup>1</sup> Similarly, an in vitro study conducted in cultured hepatocytes found that clearance of erlotinib was decreased approximately 1.9- to 16-fold by the strong CYP3A4 inhibitors ketoconazole and ritonavir.<sup>2</sup> As a result of this apparent interaction, the erlotinib prescribing information recommends avoiding this combination when possible, and when the combination must be used, decreasing the erlotinib dose by 50 mg decrements if patients experience severe adverse reactions.<br><br>The likely mechanism for this interaction is a decrease in the CYP3A-mediated metabolism of erlotinib, as erlotinib metabolism is primarily mediated by CYP3A4 with some additional contribution by CYP1A2.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. <i>Eur J Clin Pharmacol</i>. 2008;64(1):31-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18000659\">[PubMed 18000659]</a></p>\n<p>2. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metab Dispos</i>. 2013;41(10):1843-1851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23913028\">[PubMed 23913028]</a></p>\n<p>3. <i>Tarceva</i> (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals, LLC; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8731":"<p><b>Title</b> Erlotinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of severe adverse reactions (e.g., severe diarrhea, severe skin reactions, etc.). If severe adverse reactions do occur, reduce the erlotinib dose (in 50 mg decrements).</p> \n<p><b>Discussion</b> Specific data concerning the use of erlotinib with grapefruit juice are not available, but given the moderate CYP3A4 inhibition of grapefruit, the erlotinib prescribing information cautions that dose reductions may be needed with use of the combination and that the combination should be avoided when possible.<br><br>The erlotinib AUC and maximum serum concentration (Cmax) were increased by an average of 1.7- and 1.5-fold, respectively, with concomitant administration of the strong CYP3A4 inhibitor ketoconazole (200 mg twice/day for 5 days) in a study of 12 healthy volunteers.<sup>1</sup> Similarly, an in vitro study conducted in cultured hepatocytes found that clearance of erlotinib was decreased approximately 1.9- to 16-fold by the strong CYP3A4 inhibitors ketoconazole and ritonavir.<sup>2</sup> As a result of this apparent interaction, the erlotinib prescribing information recommends avoiding similar combinations when possible, and when such combinations must be used, decreasing the erlotinib dose by 50 mg decrements if patients experience severe adverse reactions.<br><br>The likely mechanism for this interaction is a decrease in the CYP3A-mediated metabolism of erlotinib, as erlotinib metabolism is primarily mediated by CYP3A4 with some additional contribution by CYP1A2.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. <i>Eur J Clin Pharmacol</i>. 2008;64(1):31-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18000659\">[PubMed 18000659]</a></p>\n<p>2. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metab Dispos</i>. 2013;41(10):1843-1851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23913028\">[PubMed 23913028]</a></p>\n<p>3. <i>Tarceva</i> (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals, LLC; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8732":"<p><b>Title</b> Tacrolimus (Systemic) / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor renal function more closely when tacrolimus is given in combination with a nonsteroidal anti-inflammatory agent.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Two published case reports describe liver transplant recipients who experienced reversible acute renal failure after ibuprofen was added to tacrolimus treatment.<sup>1</sup> One patient required hospitalization and dialysis. The roles of tacrolimus and ibuprofen in causing renal injury in these cases are unclear, although an increased risk of renal failure is possible with combined use of these agents based on their independent nephrotoxic effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sheiner PA, Mor E, Chodoff L, et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. <i>Transplantation</i>. 1994;57(7):1132-1133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7513099\">[PubMed 7513099]</a></p>\n<p>2. <i>Arthrotec</i> (diclofenac/misoprostol) [prescribing information]. New York, NY: Pfizer Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8736":"<p><b>Title</b> HYDROcodone / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of HYDROcodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients taking hydrocodone, monitor for decreased effects and withdrawal symptoms if a strong CYP3A4 inducer is initiated. Conversely, monitor patients for increased hydrocodone toxicities, including fatal respiratory depression, if a strong CYP3A4 inducer is discontinued. Consider hydrocodone dose adjustments until stable effects of the CYP3A4 inducer (either addition or removal) are achieved.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The prescribing information for at least one hydrocodone product (Zohydro ER) warns that CYP3A4 inducers may increase the metabolism of hydrocodone and lead to decreased plasma concentrations, since CYP3A4 plays a major role in hydrocodone metabolism.<sup>1</sup> Lack of efficacy, or development of a withdrawal syndrome could occur. The prescribing information also contains a boxed warning detailing that discontinuation of any CYP3A4 inducer in hydrocodone treated patients could result in an increase in hydrocodone plasma concentrations. This may prolong adverse drug effects and potentially lead to fatal respiratory depression. Monitor patients closely who are taking or discontinuing CYP3A4 inducers, and consider hydrocodone dose adjustments until stable drug effects are achieved.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zohydro ER</i> (hydrocodone bitartrate) [prescribing information]. San Diego, CA: Zogenix Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8737":"<p><b>Title</b> HYDROcodone / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The significance of this interaction may be greater in patients who are also receiving a CYP2D6 inhibitor or with use of a CYP3A4 inhibitor that also inhibits CYP2D6, as CYP2D6 is partially responsible for hydrocodone metabolism.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased hydrocodone toxicities, including fatal respiratory depression, if combined with a strong CYP3A4 inhibitor. Monitor patients at frequent intervals and consider hydrocodone dose reductions until stable drug effects are achieved.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The prescribing information for at least one hydrocodone product (Zohydro ER) contains a boxed warning detailing that concomitant use of hydrocodone and any CYP3A4 inhibitor could result in an increase in hydrocodone plasma concentrations, since CYP3A4 plays a major role in hydrocodone metabolism.<sup>1</sup> This increase in plasma concentrations may prolong adverse drug effects and potentially lead to fatal respiratory depression. If coadministration of a CYP3A4 inhibitor and hydrocodone is necessary, monitor patients for sedation and respiratory depression at frequent intervals and consider hydrocodone dose reductions until stable drug effects are achieved.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zohydro ER</i> (hydrocodone bitartrate) [prescribing information]. San Diego, CA: Zogenix Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8738":"<p><b>Title</b> DULoxetine / CYP1A2 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Strong) may increase the serum concentration of DULoxetine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the use of duloxetine in combination with a strong CYP1A2 inhibitor.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Strong) Interacting Members</b> FluvoxaMINE*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 14 male smokers, fluvoxamine (100 mg daily for 16 days) increased the maximum concentration and AUC of duloxetine (60 mg single oral dose on fluvoxamine day 12) by 2.4- and 5.6-fold, respectively.<sup>1,2</sup> In a clinical study of 13 patients with depression receiving duloxetine with a suboptimal response, fluvoxamine 25 mg/day increased the duloxetine AUC by approximately 3-fold and further increases were reported in 3 patients given fluvoxamine 50 mg/day.<sup>3</sup> <br><br>According to the duloxetine US prescribing information, concurrent use of duloxetine with potent CYP1A2 inhibitors should be avoided, <sup>2</sup> and such combined use is a listed contraindication in the duloxetine Canadian product monograph.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Paulzen M, Finkelmeyer A, Grozinger M. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. <i>Pharmacopsychiatry</i>. 2011;44(7):317-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21979923\">[PubMed 21979923]</a></p>\n<p>2. Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; July 2014.</p>\n<p>3. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. <i>Clin Pharmacokinet</i>. 2008;47(3):191-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18307373\">[PubMed 18307373]</a></p>\n<p>4. Cymbalta (duloxetine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc.; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8739":"<p><b>Title</b> Naloxegol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of naloxegol and a strong CYP3A4 inhibitor should be strictly avoided. The combination is specifically listed as a contraindication in naloxegol prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The naloxegol (25 mg single dose) AUC and maximum serum concentration (Cmax) increased 12.9-fold and 9.6-fold, respectively, when administered following a course of ketoconazole (400 mg daily for multiple doses) in healthy volunteers.<sup>1,2</sup><br><br>Naloxegol is both a CYP3A4 and P-glycoprotein (P-gp) substrate, both of which ketoconazole strongly inhibits, and this is the likely mechanism for the interaction.<sup>1,2</sup> As such, naloxegol prescribing information lists the use of naloxegol and a strong CYP3A4 inhibitor as a contraindication.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A modulators on the pharmacokinetics of naloxegol. <i>J Clin Pharmacol</i>. 2016;56(8):1019-1027. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26678015\">[PubMed 26678015]</a></p>\n<p>2. Movantik (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8740":"<p><b>Title</b> Naloxegol / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of toxicity, specifically signs and symptoms of opiate withdrawal syndrome (eg, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The naloxegol (25 mg single dose) AUC and maximum serum concentration (Cmax) increased 3.4-fold and 2.9-fold, respectively, when administered following a course of extended release diltiazem (240 mg daily for multiple doses) in healthy volunteers.<sup>1,2</sup><br><br>The likely mechanism for this interaction is diltiazem inhibition of CYP3A4, the enzyme responsible for naloxegol metabolism.<sup>1,2</sup> As such, naloxegol prescribing information recommends that the use of naloxegol and moderate CYP3A4 inhibitors be avoided. If concomitant use cannot be avoided, the dose of naloxegol should be reduced to 12.5 mg once daily and close monitoring for signs of toxicity, specifically signs and symptoms of opiate withdrawal syndrome (eg, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability) should occur.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A modulators on the pharmacokinetics of naloxegol. <i>J Clin Pharmacol</i>. 2016;56(8):1019-1027. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26678015\">[PubMed 26678015]</a></p>\n<p>2. Movantik (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8741":"<p><b>Title</b> Naloxegol / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the combination of naloxegol and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The naloxegol (25 mg single dose) AUC and maximum serum concentration (Cmax) decreased 89% and 76%, respectively, when administered following a course of rifampin (600 mg daily for multiple doses) in healthy volunteers.<sup>1,2</sup><br><br>The likely mechanism for this interaction is rifampin induction of CYP3A4, the enzyme responsible for naloxegol metabolism.<sup>1,2</sup> As such, naloxegol prescribing information states that the use of naloxegol and strong CYP3A4 inducers is not recommended because the decreased plasma concentrations of naloxegol may result in reduced efficacy.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A modulators on the pharmacokinetics of naloxegol. <i>J Clin Pharmacol</i>. 2016;56(8):1019-1027. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26678015\">[PubMed 26678015]</a></p>\n<p>2. Movantik (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8742":"<p><b>Title</b> Naloxegol / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased naloxegol toxicity, specifically signs and symptoms of opiate withdrawal syndrome (eg, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability), if naloxegol is combined with a P-glycoprotein inhibitor.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> The naloxegol (25 mg single dose) AUC and maximum serum concentration (Cmax) increased an average of 1.4-fold and 2.5-fold, respectively, when administered with the P-glycoprotein (P-gp) inhibitor quinidine (600 mg single dose) in healthy volunteers.<sup>1,2</sup><br><br>Based on these pharmacokinetic changes, the naloxegol prescribing information recommends no dose adjustment when naloxegol is combined with a P-gp inhibitor as long as the inhibitor has no more than a weak inhibitory effect on CYP3A4 (eg, quinidine).<sup>2</sup> See specific monographs for recommendations for naloxegol use when combined with P-gp inhibitors that are also moderate or strong inhibitors of CYP3A4.<br><br>The likely mechanism for this interaction is quinidine inhibition of P-gp, a transporter responsible for naloxegol efflux. Quinidine is also a weak CYP3A4 inhibitor, the enzyme responsible for the majority of naloxegol metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. <i>J Clin Pharmacol</i>. 2016;56(4):497-505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26248047\">[PubMed 26248047]</a></p>\n<p>2. Movantik (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8743":"<p><b>Title</b> Naloxegol / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Naloxegol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid the consumption of grapefruit or grapefruit juice while taking naloxegol.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the naloxegol prescribing information, naloxegol (25 mg single dose) AUC and maximum serum concentration (Cmax) increased 3.4-fold and 2.9-fold, respectively, when administered following a course of extended release diltiazem (240 mg daily for multiple doses).<sup>1</sup> Naloxegol AUC and Cmax increased 12.9-fold and 9.6-fold, respectively, when administered following a course of ketoconazole (400 mg daily for multiple doses).<sup>1</sup><br><br>Although no clinical studies have been conducted with grapefruit juice and naloxegol, grapefruit juice is known to inhibit intestinal CYP3A4 (as does diltiazem and ketoconazole). Since CYP3A4 is a responsible for the majority of naloxegol metabolism, prescribing information recommends avoidance of grapefruit juice during treatment with naloxegol because increased naloxegol plasma concentrations (and associated toxicities) would be expected.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Movantik</i> (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8744":"<p><b>Title</b> Naloxegol / Opioid Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of naloxegol with other opioid antagonists.</p>\n<div>\n <p><b>Opioid Antagonists Interacting Members</b> Alvimopan, Methylnaltrexone, Naldemedine, Nalmefene, Naloxegol, Naloxone, Naltrexone</p>\n</div> \n<p><b>Discussion</b> According to the naloxegol prescribing information, the use of naloxegol with another opioid antagonist may result in additive opioid receptor antagonism and an increased risk of opioid withdrawal (eg, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Movantik</i> (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8745":"<p><b>Title</b> Fosphenytoin-Phenytoin / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider using an alternative H<sub>2</sub>-antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Several case reports describe increases in phenytoin concentrations and/or phenytoin toxicity with associated with concurrent cimetidine.<sup>1,2,3</sup> Many relatively small clinical studies have similarly reported significant increases in phenytoin concentrations and/or decreases in phenytoin clearance with cimetidine.<sup>4,5,6,7,8,9,10</sup> Higher doses of cimetidine (e.g., 1000-1200 mg/day) appear to affect phenytoin more than lower doses, with one study of cimetidine 200 mg twice/day reporting no significant change in average phenytoin concentrations.<sup>11</sup> Of note, other case reports have described thrombocytopenia or granulocytopenia in patients receiving phenytoin and cimetidine.<sup>12,13,14</sup> Whether these reports represent an extension of the interaction described in these other reports, or whether these reflect a unique toxicity associated with the combination is unknown.<br><br>The mechanism of this interaction appears to be cimetidine inhibition of phenytoin metabolism. As other H2-receptor blockers such as famotidine or ranitidine have considerably less of an impact on drug metabolizing enzymes than cimetidine, they would be much less likely to interact. Though a study with famotidine appears to confirm this lack of an interaction,<sup>10</sup> studies/reports with ranitidine have been mixed.<sup>15,16,17</sup> Two reports describe increased phenytoin concentrations with addition of ranitidine,<sup>15,16</sup> while another report describes no interaction with concurrent ranitidine and phenytoin.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hetzel DJ, Bochner F, Hallpike JF, et al, “Cimetidine Interaction with Phenytoin,” <i>Br Med J (Clin Res Ed)</i>, 1981, 282:1512. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6786537\">[PubMed 6786537]</a></p>\n<p>2. Algozzine GJ, Steward RB, and Springer PK, “Decreased Clearance of Phenytoin with Cimetidine,” <i>Ann Intern Med</i>, 1981, 95:244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7258891\">[PubMed 7258891]</a></p>\n<p>3. Phillips P, Hansky J, “Phenytoin Toxicity Secondary to Cimetidine Administration,” <i>Med J Aust</i>, 1984, 141(9):602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6092884\">[PubMed 6092884]</a></p>\n<p>4. Neuvonen PJ, Tokola RA, Kaste M, “Cimetidine-Phenytoin Interaction: Effect on Serum Phenytoin Concentration and Antipyrine Test,” <i>Eur J Clin Pharmacol</i>, 1981, 21(3):215-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7318881\">[PubMed 7318881]</a></p>\n<p>5. Frigo GM, Lecchini S, Caravaggi M, et al, “Reduction of Phenytoin Clearance Caused by Cimetidine,” <i>Eur J Clin Pharmacol</i>, 1983, 25(1):135-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6617717\">[PubMed 6617717]</a></p>\n<p>6. Bartle WK, Walker SE, and Shapero I, “Dose-Dependent Effect of Cimetidine on Phenytoin Kinetics,” <i>Clin Pharmacol Ther</i>, 1983, 33:649-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6839635\">[PubMed 6839635]</a></p>\n<p>7. Salem RB, Breland BD, Mishra SK, et al, “Effect of Cimetidine on Phenytoin Serum Levels,” <i>Epilepsia</i>, 1983, 24(3):284-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6851961\">[PubMed 6851961]</a></p>\n<p>8. Iteogu MO, Murphy JE, Shleifer N, et al, “Effect of Cimetidine on Single-Dose Phenytoin Kinetics,” <i>Clin Pharm</i>, 1983, 2:302, 304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6883958\">[PubMed 6883958]</a></p>\n<p>9. Levine M, Jones MW, Sheppard I, “Differential Effect of Cimetidine on Serum Concentrations of Carbamazepine and Phenytoin,” <i>Neurology</i>, 1985, 35(4):562-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3982643\">[PubMed 3982643]</a></p>\n<p>10. Sambol NC, Upton RA, Chremos AN, et al, “A Comparison of the Influence of Famotidine and Cimetidine on Phenytoin Elimination and Hepatic Blood Flow,” <i>Br J Clin Pharmacol</i>, 1989, 27(1):83-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2565119\">[PubMed 2565119]</a></p>\n<p>11. Rafi JA, Frazier LM, Driscoll-Bannister SM, et al, “Effect of Over-the-Counter Cimetidine on Phenytoin Concentrations in Patients with Seizures,” <i>Ann Pharmacother</i>, 1999, 33(7-8):769-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10466901\">[PubMed 10466901]</a></p>\n<p>12. Wong YY, Lichtor T, Brown FD, “Severe Thrombocytopenia Associated with Phenytoin and Cimetidine Therapy,” <i>Surg Neurol</i>, 1985, 23(2):169-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3966212\">[PubMed 3966212]</a></p>\n<p>13. Sazie E and Jaffe JP, “Severe Granulocytopenia With Cimetidine and Phenytoin,” <i>Ann Intern Med</i>, 1980, 93:151-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7396305\">[PubMed 7396305]</a></p>\n<p>14. Yue CP, Mann KS, Chan KH, “Severe Thrombocytopenia Due to Combined Cimetidine and Phenytoin Therapy,” <i>Neurosurgery</i>, 1987, 20(6):963-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3614578\">[PubMed 3614578]</a></p>\n<p>15. Bramhall D, Levine M, “Possible Interaction of Ranitidine with Phenytoin,” <i>Drug Intell Clin Pharm</i>, 1988, 22(12):979-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3243180\">[PubMed 3243180]</a></p>\n<p>16. Tse CS, Akinwande KI, Biallowons K, “Phenytoin Concentration Elevation Subsequent to Ranitidine Administration,” <i>Ann Pharmacother</i>, 1993, 27(12):1448-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8305773\">[PubMed 8305773]</a></p>\n<p>17. Watts RW, Hetzel DJ, Bochner F, et al, “Lack of Interaction Between Ranitidine and Phenytoin,” <i>Br J Clin Pharmacol</i>, 1983, 15:499-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6303375\">[PubMed 6303375]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8746":"<p><b>Title</b> Naltrexone / GlyBURIDE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> GlyBURIDE may increase the serum concentration of Naltrexone. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for increased effects/toxicity of naltrexone in patients receiving glyburide.</p> \n<p><b>Discussion</b> In a clinical study summarized in naltrexone/bupropion US prescribing information, coadministration of glyburide (6 mg single dose) and oral glucose with naltrexone increased the maximum concentration and AUC of naltrexone by 2 fold.<sup>1</sup> The mechanism of this interaction and the independent contributions of glyburide and oral glucose are unknown.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Contrave</i> (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8747":"<p><b>Title</b> Fosphenytoin-Phenytoin / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Increase monitoring of serum phenytoin concentrations when starting (or stopping) allopurinol.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> A single case report describes a 13-year-old phenytoin-treated boy who became somnolent and experienced a 2.8-fold increase in his serum phenytoin level 7 days after starting allopurinol (150 mg daily).<sup>1</sup> He ultimately required a 23% and 35% decrease in his phenytoin dose while taking allopurinol 150 mg and 200 mg daily, respectively. <br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yokochi K, Yokochi A, Chiba K, Ishizaki T. Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. <i>Ther Drug Monit</i>. 1982;4(4):353-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7157458\">[PubMed 7157458]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8748":"<p><b>Title</b> Acetaminophen / Fosphenytoin-Phenytoin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients receiving larger doses (and longer duration) of acetaminophen may be at higher risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for acetaminophen induced hepatotoxicity if a large dose (or long term use) of acetaminophen is used in a patient taking phenytoin or fosphenytoin. Decreased effects of acetaminophen may also be seen.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> In one study, the steady-state plasma concentration of acetaminophen (APAP) was 17% lower after treatment with phenytoin (100 mg every 8 hours for 11 days).<sup>1</sup> In other clinical studies comparing epileptic patients taking phenytoin (either alone or combined with other agents) with healthy controls, the APAP AUC was 31% to 41% lower, clearance was 46% higher, and the half-life was 21% to 28% shorter in the epileptic patients.<sup>2,3,4</sup> This decreased exposure could reduce therapeutic response to acetaminophen, but such an effect has not been reported. Of more concern is the possibility of increased production of the toxic acetaminophen metabolite (N-acetyl-p-benzoquinone imine [NAPQI]) in the presence of phenytoin therapy. Several case reports describe patients taking phenytoin who experienced liver toxicity (ranging from elevations in liver function tests, coagulopathy, encephalopathy, fulminant liver failure requiring transplantation, and death) after acute ingestion of acetaminophen (25 g to 45 g).<sup>5,6,7</sup> In all cases, acetaminophen levels were relatively low and only one patient received N-acetylcysteine (NAC). The authors of each report suggest that the severity of liver dysfunction experienced was out of proportion to the measured serum APAP level suggesting phenytoin played a contributory role. Another case report describes a patient on phenytoin therapy who experienced elevations in liver function tests after ingesting 1,300 mg to 6,200 mg of APAP daily for 10 days.<sup>8</sup> Phenytoin concentrations do not appear to be affected by acetaminophen.<sup>9</sup><br><br>The exact mechanism of an interaction between acetaminophen and phenytoin is not clear. Normally, 80% to 90% of APAP undergoes conjugation via 5-diphosphate-glucuronosyltranferases (UGTs) to inactive, nontoxic metabolites. Approximately 10% of the dose is oxidized via CYP enzymes to the toxic NAPQI metabolite. NAPQI is rapidly conjugated, in the presence of adequate stores of glutathione, to form additional nontoxic metabolites that are then excreted. It has been proposed that phenytoin may induce CYP enzymes, thus increasing the formation of NAPQI.<sup>8</sup> Additionally, in vitro studies suggest that phenytoin may inhibit several UGTs and shunt metabolism to increase formation of NAPQI.<sup>10,11</sup> However, other studies suggest that phenytoin may induce UGTs rather than inhibit them,<sup>12,13</sup> and an increase in the formation of the glucoronide conjugate has been reported with phenytoin use.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cunningham JL, Evans DA. Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction? <i>Br J Clin Pharmacol</i>. 1981;11(6):591-595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7272175\">[PubMed 7272175]</a></p>\n<p>2. Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. <i>Br J Clin Pharmacol</i>. 1979;7(2):201-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>3. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. <i>Clin Pharmacol Ther</i>. 1984;35(4):480-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p>4. Prescott LF, Critchley JA, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. <i>Br J Clin Pharmacol</i>. 1981;12(2):149-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7306429\">[PubMed 7306429]</a></p>\n<p>5. Minton NA, Henry JA, Frankel RJ. Fatal paracetamol poisoning in an epileptic. <i>Hum Toxicol</i>. 1988;7(1):33-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346037\">[PubMed 3346037]</a></p>\n<p>6. McClements BM, Hyland M, Callender ME, Blair TL. Management of paracetamol poisoning complicated by enzyme induction due to alcohol or drugs. <i>Lancet</i>. 1990;335(8704):1526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1972451\">[PubMed 1972451]</a></p>\n<p>7. Suchin SM, Wolf DC, Lee Y, et al. Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. <i>Dig Dis Sci</i>. 2005;50(10):1836-1838. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16187183\">[PubMed 16187183]</a></p>\n<p>8. Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen heptatoxcity: case report and review of the literature. <i>Pharmacotherapy</i>. 2000;20(2):229-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10678302\">[PubMed 10678302]</a></p>\n<p>9. Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. <i>Eur J Clin Pharmacol</i>. 1979;15(4):263-268. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=314381\">[PubMed 314381]</a></p>\n<p>10. Kostrubsky SE, Sinclair JF, Strom SC, et al. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. <i>Toxicol Sci</i>. 2005;87(1):146-155. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15933229\">[PubMed 15933229]</a></p>\n<p>11. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkami S, Kostrubsky S. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9, and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. <i>Chem Res Toxicol</i>. 2006;19(5):701-709. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16696573\">[PubMed 16696573]</a></p>\n<p>12. Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. <i>Eur J Clin Pharmacol</i>. 1987;31(6):677-683. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3556375\">[PubMed 3556375]</a></p>\n<p>13. Bock KW, Bock-Hennig BS. Differential induction of human liver UDP-glucuronosyltransferase activities by phenobarbital-type inducers. <i>Biochem Pharmacol</i>. 1987;36(23):4137-4143. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2825716\">[PubMed 2825716]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8749":"<p><b>Title</b> CarBAMazepine / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of carbamazepine toxicity when using ciprofloxacin.</p> \n<p><b>Discussion</b> The carbamazepine AUC and maximum serum concentration (Cmax) were an average of 54% and 68% higher, respectively, with concurrent ciprofloxacin in a study of 8 healthy volunteers who received carbamazepine 200 mg (single dose) with or without concurrent ciprofloxacin 500 mg (single dose).<sup>1</sup> Considering that carbamazepine induces its own metabolism with chronic therapy,<sup>2</sup> the degree to which this single-dose interaction study would be representative of what would happen in patients on chronic carbamazepine therapy is unknown.<br><br>The mechanism for this potential interaction is uncertain but may be ciprofloxacin inhibition of the CYP3A-mediated metabolism of carbamazepine.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>2. <i>Tegretol</i> (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8750":"<p><b>Title</b> Phenytoin / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to oral dosage forms of phenytoin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Phenytoin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action is required for most patients. Consider monitoring serum phenytoin levels and/or staggering administration of these agents in high risk patients.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Data regarding the effect of antacids on phenytoin are inconsistent. Pharmacokinetic studies report that when phenytoin was administered with various antacids (aluminum hydroxide, magnesium hydroxide, magnesium oxide, calcium carbonate, or magnesium trisilicate), phenytoin serum levels decreased by 16% and the AUC of phenytoin decreased 21% to 27%.<sup>1,2,3,4</sup> In contrast, other studies have shown that administration of phenytoin with antacid therapies (magnesium trisilicate, aluminum hydroxide, magnesium hydroxide, calcium carbonate, or calcium gluconate) resulted in no change in phenytoin AUC, maximum serum concentration (Cmax), or the time to reach maximum serum concentration (tmax).<sup>1,3,5,6</sup><br><br>The mechanism for these interactions is unknown but may be related to changes in gastric pH or phenytoin adsorption onto the antacid, leading to impaired absorption. The clinical relevance of this data is uncertain, as the magnitude of the pharmacokinetic changes appears small and is inconsistent among studies. Phenytoin prescribing information suggests separating the administration of phenytoin and antacids to avoid this interaction,<sup>7</sup> although this strategy has not been evaluated in a clinical study.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kulshrestha VK, Thomas M, Wadsworth J, Richens A. Interaction between phenytoin and antacids. <i>Br J Clin Pharmacol</i>. 1978;6(2):177-179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=678395\">[PubMed 678395]</a></p>\n<p>2. Garnett WR, Carter BL, Pellock JM. Effect of calcium and antacids on phenytoin bioavailability. <i>Arch Neurol</i>. 1980;37(7):467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7387502\">[PubMed 7387502]</a></p>\n<p>3. Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. <i>Ther Drug Monit</i>. 1981;3(4):333-340. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7336470\">[PubMed 7336470]</a></p>\n<p>4. McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. <i>Br J Clin Pharmacol</i>. 1982;13(4):501-505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7066165\">[PubMed 7066165]</a></p>\n<p>5. Chapron DJ, Kramer PA, Mariano SL, Hohnadel DC. Effect of calcium and antacids on phenytoin bioavailability. <i>Arch Neurol</i>. 1979;36(7):436-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=454247\">[PubMed 454247]</a></p>\n<p>6. O'Brien LS, Orme ML, Breckenridge AM. Failure of antacids to alter the pharmacokinetics of phenytoin. <i>Br J Clin Pharmacol</i>. 1978;6(2):176-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=678394\">[PubMed 678394]</a></p>\n<p>7. <i>Dilantin</i> (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8751":"<p><b>Title</b> Fosphenytoin-Phenytoin / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of osteomalacia and rickets if fosphenytoin or phenytoin is combined with long-term use of a carbonic anhydrase inhibitor.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Long-term use of phenytoin has been associated with the development of decreased bone mineral density (osteopenia, osteoporosis, osteomalacia, and rickets) due to increased vitamin D metabolism and subsequent hypovitaminosis D, hypocalcemia, and hypophosphatemia.<sup>1</sup> Carbonic anhydrase inhibitors can result in metabolic acidosis, which if left untreated, may also result in osteomalacia, rickets, or osteoporosis.<sup>2,3,4,5</sup> Several case reports describe the development of severe osteomalacia, that was possibly accelerated, by the combination of acetazolamide and phenytoin.<sup>6,7,8,9</sup> Prescribing information for acetazolamide warns that administration of acetazolamide to patients receiving long-term phenytoin therapy may increase or enhance the development of osteomalacia.<sup>3</sup> Caution and increased monitoring are advised.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dilantin</i> (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; March 2014. </p>\n<p>2. <i>Neptazane</i> (methazolamide) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; April 2010.</p>\n<p>3. <i>Diamox</i> (acetazolamide) [prescribing information]. Pomona, NY: Duramed Pharmaceuticals Inc; November 2004.</p>\n<p>4. <i>Topamax</i> (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2014.</p>\n<p>5. <i>Zonegran</i> (zonisamide) [pescribing information]. Woodcliff Lake, NJ: Elan Pharma International Ltd; April 2009.</p>\n<p>6. Mallette LE. Letter: Anticonvulsants, acetazolamide and osteomalacia. <i>N Engl J Med</i>. 1975;293(13):668. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1152917\">[PubMed 1152917]</a></p>\n<p>7. Matsuda I, Takekoshi Y, Shida N, Fujieda K, Nagai B. Renal tubular acidosis and skeletal demineralization in patients on long-term anticonvulsant therapy. <i>J Pediatr</i>.1975;87(2):202-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=239108\">[PubMed 239108]</a></p>\n<p>8. Mallette LE. Acetazolamide-accelerated anticonvulsant osteomalacia. <i>Arch Intern Med</i>. 1977;137(8):1013-1017. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=879939\">[PubMed 879939]</a></p>\n<p>9. Ishitsu T, Matsuda I, Seino Y, Kann H. Anticonvulsant-induced rickets associated with renal tubular acidosis and normal level of serum 1,25-dihydroxyvitamin D. <i>Am J Dis Child</i>. 1981;135(12):1140-1142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6895575\">[PubMed 6895575]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8752":"<p><b>Title</b> Phenytoin / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mianserin may diminish the therapeutic effect of Phenytoin. Phenytoin may decrease the serum concentration of Mianserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor the clinical response to both phenytoin and mianserin closely when using this combination. Closer monitoring of serum concentrations is recommended, and dose adjustments of one or both drugs may be necessary. Additionally, mianserin may decrease the seizure threshold, increasing the likelihood of a seizure, particularly in patients with other risk factors for seizure activity.</p> \n<p><b>Discussion</b> Although specific data regarding this combination are not available, different mianserin summaries of product characteristics warn about a potential interaction and recommend monitoring of phenytoin concentrations and a possible need to increase the mianserin dose.<sup>1,2,3</sup><br><br>A study with mirtazapine, which is very similar to mianserin in chemical structure, reported an average 47% decrease in mirtazapine AUC following the initiation of phenytoin (200 mg/day) in 17 volunteers.<sup>4</sup><br><br>An additional concern with this combination is the potential for mianserin to decrease the seizure threshold,<sup>1,2,3,5</sup> an effect that may increase the potential for seizure activity in phenytoin-treated patients, particularly in those patients with other risk factors for seizure activity.<br><br>The mechanism(s) for this potential interaction is/are uncertain. Phenytoin is a known inducer of CYP3A4 and other metabolic enzymes, so induction of mianserin metabolism is at least one likely mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>2. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>3. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>4. Spaans E, van den Heuvel MW, Schnabel PG, et al. Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. <i>Eur J Clin Pharmacol</i>. 2002;58(6):423-429. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12242602\">[PubMed 12242602]</a></p>\n<p>5. Borowicz KK, Banach M, Zarczuk R, Lukasik D, Luszczki JJ, Czuczwar SJ. Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. <i>Psychopharmacology (Berl)</i>. 2007;195(2):167-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17653694\">[PubMed 17653694]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8753":"<p><b>Title</b> Fosphenytoin / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mianserin may diminish the therapeutic effect of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Mianserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor the clinical response to both phenytoin and mianserin closely when using this combination. Closer monitoring of serum concentrations is recommended, and dose adjustments of one or both drugs may be necessary. Additionally, mianserin may decrease the seizure threshold, increasing the likelihood of a seizure, particularly in patients with other risk factors for seizure activity.</p> \n<p><b>Discussion</b> Although specific data regarding this combination are not available, different mianserin summaries of product characteristics warn about a potential interaction and recommend monitoring of phenytoin concentrations and a possible need to increase the mianserin dose.<sup>1,2,3</sup><br><br>A study with mirtazapine, which is very similar to mianserin in chemical structure, reported an average 47% decrease in mirtazapine AUC following the initiation of phenytoin (200 mg/day) in 17 volunteers.<sup>4</sup><br><br>An additional concern with this combination is the potential for mianserin to decrease the seizure threshold,<sup>1,2,3,5</sup> an effect that may increase the potential for seizure activity in phenytoin-treated patients, particularly in those patients with other risk factors for seizure activity.<br><br>The mechanism(s) for this potential interaction is/are uncertain. Phenytoin is a known inducer of CYP3A4 and other metabolic enzymes, so induction of mianserin metabolism is at least one likely mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>2. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>3. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>4. Spaans E, van den Heuvel MW, Schnabel PG, et al. Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. <i>Eur J Clin Pharmacol</i>. 2002;58(6):423-429. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12242602\">[PubMed 12242602]</a></p>\n<p>5. Borowicz KK, Banach M, Zarczuk R, Lukasik D, Luszczki JJ, Czuczwar SJ. Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. <i>Psychopharmacology (Berl)</i>. 2007;195(2):167-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17653694\">[PubMed 17653694]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8754":"<p><b>Title</b> Tacrolimus (Systemic) / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> No action required beyond the standard monitoring of tacrolimus serum levels and renal function that accompanies the routine use of tacrolimus.</p> \n<p><b>Discussion</b> Two case reports describe increases in tacrolimus levels along with decreases in renal function after metronidazole was initiated in tacrolimus-treated patients.<sup>1,2</sup> In the first case, tacrolimus concentrations nearly doubled and a 60% reduction in tacrolimus dose was required to maintain therapeutic concentrations.<sup>1</sup> After metronidazole discontinuation, tacrolimus concentrations fell 72%. In the second case, tacrolimus concentrations increased 2.7-fold, requiring a 67% reduction in tacrolimus dose.<sup>2</sup><br><br>In contrast, a retrospective study of 35 patients on tacrolimus found that treatment of Clostridium difficile infection (CDI) with metronidazole resulted in negligible changes to dose-normalized tacrolimus concentrations.<sup>3</sup> Dose-normalized tacrolimus concentrations increased slightly (but not statistically significantly) after CDI diagnosis but prior to metronidazole initiation.<sup>3</sup> Patients who received oral vancomycin (n = 17) also had negligible changes to their dose-normalized tacrolimus concentrations.<sup>3</sup> <br><br>The mechanism of this potential interaction is unknown. Metronidazole is a weak inhibitor of CYP3A4, a major metabolizing enzyme for tacrolimus elimination, and may explain these observations. However, in both case reports, metronidazole was used for the treatment of infectious diarrhea, a condition associated with increases in tacrolimus concentrations.<sup>4,5,6,7,8</sup> It is unclear if the presence of diarrhea alone, the addition of metronidazole, or other factors contributed to the increases in tacrolimus serum levels.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Herzig K, Johnson DW. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. <i>Nephrol Dial Transplant</i>. 1999;14(2):521-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10069238\">[PubMed 10069238]</a></p>\n<p>2. Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. <i>Ann Pharmacother</i>. 2005;39(6):1109-1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15855244\">[PubMed 15855244]</a></p>\n<p>3. Early CR, Park JM, Dorsch MP, Pogue KT, Hanigan SM. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile. <i>Transpl Infect Dis</i>. 2016;18(5):714-720. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27501504\">[PubMed 27501504]</a></p>\n<p>4. Nakamura A, Amada N, Haga I, Tokodai K, Kashiwadate T. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. <i>Transplant Proc</i>. 2014;46(2):592-594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24656020\">[PubMed 24656020]</a></p>\n<p>5. Sinha R, Marks SD. Tacrolimus toxicity secondary to diarrhoea in nephrotic syndrome. <i>Acta Paediatr</i>. 2013;102(7):e291-e292. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23573873\">[PubMed 23573873]</a></p>\n<p>6. Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. <i>Am J Transplant</i>. 2002;2(10):989-992. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12484345\">[PubMed 12484345]</a></p>\n<p>7. Asano T, Nishimoto K, Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. <i>Transplant Proc</i>. 2004;36(7):2096-2097. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15518758\">[PubMed 15518758]</a></p>\n<p>8. Hochleitner BW, Bosmuller C, Nehoda H, et al. Increased tacrolimus levels during diarrhea. <i>Transpl Int</i>. 2001;14(4):230-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11512055\">[PubMed 11512055]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8755":"<p><b>Title</b> CycloSPORINE (Systemic) / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> No action required beyond the standard monitoring of cyclosporine serum levels and renal function that accompanies the routine use of cyclosporine.</p> \n<p><b>Discussion</b> Two case reports describe increases in cyclosporine levels along with decreases in renal function after metronidazole was initiated in cyclosporine-treated patients.<sup>1,2</sup> In the first case, cyclosporine trough concentrations increased 97% 3 days after metronidazole (400 mg three time daily) therapy was initiated and returned to baseline 1 week after metronidazole discontinuation.<sup>1</sup> In the second case, cyclosporine trough concentrations increased 127% after the addition of metronidazole (2,250 mg per day for 12 days) and cimetidine (800 mg per day).<sup>2</sup> Cyclosporine concentrations returned to baseline after both medications were discontinued. The contributory role of metronidazole versus that of cimetidine or the combination of both agents on cyclosporine concentrations is unknown.<br><br>The mechanism of this potential interaction is unknown. Metronidazole is a weak inhibitor of CYP3A4, a major metabolizing enzyme for cyclosporine elimination, and may explain these observations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Herzig K, Johnson DW. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. <i>Nephrol Dial Transplant</i>. 1999;14(2):521-523. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10069238\">[PubMed 10069238]</a></p>\n<p>2. Zylber-Katz E, Rubinger D, Berlatzky Y. Cyclosporine interactions with metronidazole and cimetidine. <i>Drug Intell Clin Pharm</i>. 1988;22(6):504-505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3293960\">[PubMed 3293960]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8769":"<p><b>Title</b> Trabectedin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combining trabectedin with strong CYP3A4 inhibitors whenever possible. If a strong CYP3A inhibitor for short-term use (ie, less than 14 days) must be used, administer the strong CYP3A inhibitor 1 week after the trabectedin infusion, and discontinue it the day prior to the next trabectedin infusion.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 8 patients with advanced solid tumors, coadministration of ketoconazole (200 mg twice daily for 15 doses) increased the dose-adjusted average maximum concentration and AUC of trabectedin (0.58 mg/m2 with ketoconazole or 1.3 mg/m2 without ketoconazole, administered intravenously over 3 hours) by 22% and 66%, respectively.<sup>1,2</sup> <br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated trabectedin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Machiels JP, Staddon A, Herremans C, et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. <i>Cancer Chemother Pharmacol</i>. 2014;74(4):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25100135\">[PubMed 25100135]</a></p>\n<p>2. Yondelis (trabectedin) [prescribing information]. Horsham, PA: Janssen Products LP; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8770":"<p><b>Title</b> Trabectedin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combining trabectedin with strong CYP3A4 inducers whenever possible.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 8 patients with advanced solid tumors, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily for 6 days) decreased the dose-adjusted average maximum concentration and AUC of trabectedin (1.3 mg/m2 administered intravenously over 3 hours) by 22% and 31%, respectively.<sup>1,2</sup> Results of a population pharmacokinetic analysis indicated an average 19% increase in trabectedin clearance when coadministered with the likely weaker CYP3A4 inducer dexamethasone.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is induction of CYP3A4 mediated trabectedin metabolism by rifampin or dexamethasone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Machiels JP, Staddon A, Herremans C, et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. <i>Cancer Chemother Pharmacol</i>. 2014;74(4):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25100135\">[PubMed 25100135]</a></p>\n<p>2. <i>Yondelis</i> (trabectedin) [product monograph]. Toronto, ON: Janssen Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8771":"<p><b>Title</b> Trabectedin / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased trabectedin effects/toxicities if combined with moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil<br><b>Exception</b> Grapefruit Juice</p>\n</div> \n<p><b>Discussion</b> The effect of moderate CYP3A4 inhibitors on trabectedin pharmacokinetics has not been evaluated in a clinical study. However, in a clinical study of 8 patients with advanced solid tumors, coadministration of the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 15 doses) increased the dose-adjusted average maximum concentration and AUC of trabectedin (0.58 mg/m2 with ketoconazole or 1.3 mg/m2 without ketoconazole, administered intravenously over 3 hours) by 22% and 66%, respectively.<sup>1,2</sup> <br><br>Trabectedin prescribing information recommends against coadministration of trabectedin with strong CYP3A4 inhibitors.<sup>2</sup> Although no recommendations are provided for use with moderate CYP3A4 inhibitors, monitoring for increased effects/toxicities is likely warranted when these agents are combined.<br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated trabectedin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Machiels JP, Staddon A, Herremans C, et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. <i>Cancer Chemother Pharmacol</i>. 2014;74(4):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25100135\">[PubMed 25100135]</a></p>\n<p>2. Yondelis (trabectedin) [prescribing information]. Horsham, PA: Janssen Products LP; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8772":"<p><b>Title</b> Trabectedin / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Trabectedin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combining trabectedin with St. John's wort whenever possible.</p> \n<p><b>Discussion</b> In a clinical study of 8 patients with advanced solid tumors, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily for 6 days) decreased the dose-adjusted average maximum concentration and AUC of trabectedin (1.3 mg/m2 administered intravenously over 3 hours) by 22% and 31%, respectively.<sup>1,2</sup> Results of a population pharmacokinetic analysis indicated an average 19% increase in trabectedin clearance when coadministered with the likely weaker CYP3A4 inducer dexamethasone.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is induction of CYP3A4 mediated trabectedin metabolism by rifampin or dexamethasone. Trabectedin Canadian product labeling states that its use in combination with strong CYP3A4 inducers (St. John's wort is specifically listed as an example) should be avoided whenever possible.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Machiels JP, Staddon A, Herremans C, et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. <i>Cancer Chemother Pharmacol</i>. 2014;74(4):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25100135\">[PubMed 25100135]</a></p>\n<p>2. <i>Yondelis</i> (trabectedin) [product monograph]. Toronto, ON: Janssen Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8773":"<p><b>Title</b> Opioid Antagonists / Methylnaltrexone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Methylnaltrexone may enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of methylnaltrexone with other opioid antagonists.</p>\n<div>\n <p><b>Opioid Antagonists Interacting Members</b> Alvimopan, Methylnaltrexone, Naldemedine, Nalmefene, Naloxegol, Naloxone, Naltrexone</p>\n</div> \n<p><b>Discussion</b> According to methylnaltrexone US prescribing information, the use of methylnaltrexone with another opioid antagonist may result in additive opioid receptor antagonism and an increased risk of opioid withdrawal (eg, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Relistor</i> (methylnaltrexone) [prescribing information]. Tarrytown, NY: Progenics Pharmaceuticals Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8774":"<p><b>Title</b> Lopinavir / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lopinavir. Specifically, the combination of metronidazole and lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-like reaction. MetroNIDAZOLE (Systemic) may enhance the arrhythmogenic effect of Lopinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of lopinavir/ritonavir and metronidazole should be avoided if possible. The concomitant use of highest risk QTc-prolonging agents (eg, lopinavir) with any other QTc-prolonging agent (eg, metronidazole) may substantially increase the risk for torsades de pointes or other significant ventricular tachyarrhythmias. Additionally, the use of lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-like reaction if combined with metronidazole. If these agents are used concomitantly, monitor for QTc prolongation, ventricular arrhythmias, and, if the lopinavir/ritonavir solution is used, development of a disulfiram-like reaction (eg, nausea, vomiting, flushing).</p> \n<p><b>Discussion</b> Lopinavir/ritonavir labeling warns that QTc interval prolongation was seen in a randomized study and significant QTc prolongation and torsades de pointes (TdP) have been reported during postmarketing surveillance.<sup>1</sup> As such, combination with other drugs that prolong the QTc interval should be avoided. A small number of individual reports describe QT prolongation and/or TdP associated with the use of metronidazole.<sup>2,3,4,5</sup> Product labeling also warns of the risk of a disulfiram-like reaction if metronidazole is combined with the lopinavir/ritonavir solution because it contains 42% alcohol.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>2. Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsades de pointes in a hospitalized surgical patient. <i>Sultan Qaboos Univ Med J</i>. 2013;13(1):152-155. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23573398\">[PubMed 23573398]</a></p>\n<p>3. Altin C, Kanyilmaz S, Baysal S, Ozin B. QT interval prolongation due to metronidazole administration. <i>Anadolu Kardiyol Derg</i>. 2011;11(5):468-469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21733783\">[PubMed 21733783]</a></p>\n<p>4. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de points: the contribution from data mining of the US FDA Adverse Event Reporting System. <i>Drug Saf</i>. 2010;33(4):303-314. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20297862\">[PubMed 20297862]</a></p>\n<p>5. Cohen O, Saar N, Swartzon M, Kliuk-Ben-Bassat O, Justo D. First report of metronidazole-induced QT interval prolongation. <i>Int J Antimicrob Agents</i>. 2008;31(2):180-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18082376\">[PubMed 18082376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8775":"<p><b>Title</b> Lopinavir / MetroNIDAZOLE (Topical)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: The development of a disulfiram-like reaction is only of concern with the lopinavir/ritonavir solution that contains 42% alcohol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Lopinavir. Specifically, the use of topical metronidazole with lopinavir/ritonavir solution (which contains 42% alcohol) may result in a disulfiram-like reaction. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when combining lopinavir/ritonavir solution with metronidazole, as metronidazole may interact with the alcohol in the solution to cause a disulfiram-like reaction. Closely monitor patients using this combination.</p> \n<p><b>Discussion</b> Several case reports describe signs and symptoms of a disulfiram-like reaction during coadministration of alcohol and metronidazole.<sup>1,2,3,4,5,6</sup> Reported reactions have ranged from mild cardiovascular effects to death. Randomized, double-blind, placebo-controlled trials, however, have failed to demonstrate the value of metronidazole as an alcohol aversive agent.<sup>7,8,9,10,11,12</sup> The results of these trials suggest that if a reaction does occur, it will be unpredictable and relatively mild. The mechanism of a metronidazole-alcohol interaction, if one does occur, is unclear. A disulfiram-like reaction presumes that metronidazole increases acetaldehyde concentrations by inhibiting acetaldehyde dehydrogenase, thereby inhibiting the metabolism of acetaldehyde to acetic acid. A double-blind study involving 12 normal subjects demonstrated no effect of metronidazole on acetaldehyde concentrations.<sup>13</sup><br><br>Despite the uncertainty of a true disulfiram-like reaction resulting from a metronidazole and alcohol combination, lopinavir/ritonavir prescribing information does warn of this potential interaction when lopinavir/ritonavir solution (containing 42% alcohol) is combined with metronidazole.<sup>14</sup> Systemic metronidazole absorption from topical preparations is generally low, and is probably greatest from vaginal preparations that reach single-dose maximum serum concentrations around 2% of those seen with 500 mg orally.<sup>15,16,17,18</sup> Although an interaction with alcohol is unlikely with most topical uses of metronidazole, a case report suggests some risk, particularly with vaginal preparations. <sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Taylor JA. Metronidazole - a new agent for combined somatic and psychic therapy for alcoholism. A case study and preliminary report. <i>Bull Los Angel Neuro Soc</i>. 1964;29:158-162. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14217759\">[PubMed 14217759]</a></p>\n<p>2. Sansoy OM. Evaluation of metronidazole in the treatment of alcoholism. A comprehensive three-year study comprising 60 cases. <i>Rocky Mt Med J</i>. 1970;67(2):43-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5417823\">[PubMed 5417823]</a></p>\n<p>3. Alexander I. “Alcohol-antabuse” syndrome in patients receiving metronidazole during gynaecological treatment. <i>Br J Clin Pract</i>. 1985;39(7):292-293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4027157\">[PubMed 4027157]</a></p>\n<p>4. Edwards DL, Fink PC, Van Dyke PO. Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole. <i>Clin Pharm</i>. 1986;5(12):999-1000. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3492326\">[PubMed 3492326]</a></p>\n<p>5. Plosker GL. Possible interaction between ethanol and vaginally administered metronidazole. <i>Clin Pharm</i>. 1987;6(3):189,192-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3665375\">[PubMed 3665375]</a></p>\n<p>6. Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ethanol interaction. <i>Am J Forensic Med Pathol</i>. 1996;17(4):343-346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8947362\">[PubMed 8947362]</a></p>\n<p>7. Linton PH, Hain JD. Metronidazole in the treatment of alcoholism. <i>Q J Stud Alcohol</i>. 1967;28(3):544-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4860455\">[PubMed 4860455]</a></p>\n<p>8. Egan WP, Goetz R. Effect of metronidazole on drinking by alcoholics. <i>Q J Stud Alcohol</i>. 1968;29(4):899-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4883949\">[PubMed 4883949]</a></p>\n<p>9. Penick SB, Carrier RN, Sheldon JB. Metronidazole in the treatment of alcoholism. <i>Am J Psychiatry</i>. 1969;125(8):1063-1066. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4893840\">[PubMed 4893840]</a></p>\n<p>10. Strassman HD, Adams B, Pearson AW. Metronidazole effect on social drinkers. <i>Q J Stud Alcohol</i>. 1970;31(2):394-398. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4921396\">[PubMed 4921396]</a></p>\n<p>11. Platz A, Panepinto WC, Kissin B, Charnoff SM. Metronidazole and alcoholism. (An evaluation of specific and non specific factors in drug treatment). <i>Dis Nerv Syst</i>. 1970;31(9):631-636. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4919889\">[PubMed 4919889]</a></p>\n<p>12. Kaplan R, Blume S, Rosenberg S, Pitrelli J, Turner WJ. Phenytoin, metronidazole and multivitamins in the treatment of alcoholism. <i>Q J Stud Alcohol</i>. 1972;33(1):94-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4551022\">[PubMed 4551022]</a></p>\n<p>13. Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP. Lack of disulfiram-like reaction with metronidazole and ethanol. <i>Ann Pharmacother</i>. 2002;36(6):971-974. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12022894\">[PubMed 12022894]</a></p>\n<p>14. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>15. Metronidazole topical cream [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; July 2004.</p>\n<p>16. <i>Metrogel</i> (metronidazole gel) [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; February 2007.</p>\n<p>17. Metronidazole lotion [prescribing information]. Lincolnton, NC: Actavis Mid Atlantic LLC; February 2009.</p>\n<p>18. <i>Metrogel-Vaginal</i> (metronidazole gel) [prescribing information]. Northridge, CA: 3M Pharmaceuticals; January 2001.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8776":"<p><b>Title</b> CarBAMazepine / Loxapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loxapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor carbamazepine response and concentrations of carbamazepine and its active epoxide metabolite closely when used together with loxapine, particularly after starting or stopping loxapine. Carbamazepine dose adjustment may be needed.</p> \n<p><b>Discussion</b> A case report describes a patient who experienced a 76% decrease in their carbamazepine epoxide (CBZE) to carbamazepine (CBZ) ratio following the discontinuation of loxapine.<sup>1</sup> Concentrations of CBZE also decreased by 65% following loxapine discontinuation, and a retrospective review of other patients receiving the combination of loxapine and CBZ revealed elevated CBZE/CBZ ratios similar to what had been observed in the case patient. Carbamazepine prescribing information cautions that serum concentrations should be closely monitored and that dose adjustment may be needed if carbamazepine is used with loxapine.<sup>2</sup><br><br>The specific mechanism for this apparent interaction is uncertain, but it has been proposed that loxapine may inhibit epoxide hydrolase resulting in increased concentrations of the active carbamazepine epoxide metabolite.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Collins DM, Gidal BE, Pitterle ME. Potential interaction between carbamazepine and loxapine: case report and retrospective review. <i>Ann Pharmacother</i>. 1993;27(10):1180-1187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8251682\">[PubMed 8251682]</a></p>\n<p>2. <i>Tegretol</i> (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8777":"<p><b>Title</b> CarBAMazepine / QUEtiapine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> QUEtiapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit during treatment with a strong CYP3A4 inducer such as carbamazepine. The quetiapine dose should be reduced to the previous/regular dose within 7 to 14 days of discontinuation of carbamazepine. Additionally, closely monitor carbamazepine response and concentrations of carbamazepine and its active epoxide metabolite when used together with quetiapine, particularly after starting or stopping quetiapine. Carbamazepine dose adjustment may be needed.</p> \n<p><b>Discussion</b> The quetiapine AUC and maximum serum concentration (Cmax) decreased by an average of 87% and 80%, respectively, in a study of 18 psychiatric patients receiving both carbamazepine (200 mg three times daily) and quetiapine (300 mg twice daily).<sup>1</sup> Two retrospective reviews of therapeutic drug monitoring data also describe several patients whose quetiapine serum concentration/dose ratio was substantially lower than mean values during treatment with strong CYP3A4 inducers (carbamazepine, phenobarbital).<sup>2,3</sup> The quetiapine prescribing information cautions that substantial quetiapine dose increases will likely be required if used together with carbamazepine.<sup>4,5</sup> The suspected primary mechanism of this interactions is induction of CYP3A4-mediated quetiapine metabolism by carbamazepine.<br><br>A case report also describes 2 patients who experienced 3- to 4-fold increases in the concentration of the active carbamazepine epoxide following initiation of quetiapine.<sup>6</sup> Carbamazepine prescribing information cautions that serum concentrations should be closely monitored and that dose adjustment may be needed if carbamazepine is used with quetiapine.<sup>7</sup> The specific mechanism for this apparent interaction is uncertain, but it has been proposed that quetiapine may inhibit epoxide hydrolase and/or glucuronidation of the 10,11-transdiol metabolite, resulting in increased concentrations of the active carbamazepine epoxide metabolite.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. <i>Br J Clin Pharmacol</i>. 2006;61(1):58-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16390352\">[PubMed 16390352]</a></p>\n<p>2. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. <i>Ther Drug Monit</i>. 2004;26(5):486-491. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385830\">[PubMed 15385830]</a></p>\n<p>3. Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. <i>Ther Drug Monit</i>. 2011;33(2):222-226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383647\">[PubMed 21383647]</a></p>\n<p>4. <i>Seroquel</i> (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.</p>\n<p>5. <i>Seroquel XR</i> (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.</p>\n<p>6. Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10,11-epoxide by quetiapine. <i>Pharmacotherapy</i>. 2002;22(11):1500-1503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12432977\">[PubMed 12432977]</a></p>\n<p>7. <i>Tegretol</i> (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8778":"<p><b>Title</b> Thalidomide / Erythropoiesis-Stimulating Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor patients using this combination for signs and symptoms of thromboembolism such as swelling, redness, warmth, or pain in the legs, dyspnea, tachypnea, hemoptysis, or chest pain. Advise patients of potential risks and encourage prompt reporting of any thromboembolism signs or symptoms.</p>\n<div>\n <p><b>Erythropoiesis-Stimulating Agents Interacting Members</b> Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin Lambda, Epoetin Zeta, Methoxy Polyethylene Glycol-Epoetin Beta</p>\n</div> \n<p><b>Discussion</b> Thalidomide prescribing information warns of a possible increase in the risk for thromboembolism with concomitant use of drugs that may independently increase the risk for thromboembolism, such as erythropoiesis-stimulating agents or estrogen-containing therapies, though specific data regarding the actual risks with such combinations are lacking.<sup>1</sup> The use of thalidomide itself is associated with a significant risk for thromboembolism; as described in the prescribing information, 22% of those treated with thalidomide plus dexamethasone experienced thromboembolism versus 5% of those treated with dexamethasone alone in a study of patients with multiple myeloma.<sup>1</sup><br><br>Use of the erythropoiesis-stimulating agents is also associated with a significant risk for death, myocardial infarction, stroke, and other thromboembolic events.<sup>2,3,4,5</sup><br><br>The proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Thalidomid</i> (thalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; February 2013.</p>\n<p>2. <i>Aranesp</i> (darbepoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2013.</p>\n<p>3. <i>Epogen</i> (epoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2013.</p>\n<p>4. <i>Mircera</i> (methoxy polyethylene glycol-epoetin beta) [prescribing information]. South San Francisco, CA: Hoffmann-La Roche Inc; October 2014.</p>\n<p>5. <i>Neorecormon</i> (epoetin beta) [summary of product characteristics]. Welwyn Garden City, Hertfordshire, United Kingdom: Roche Products Limited; October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8779":"<p><b>Title</b> Lenalidomide / Erythropoiesis-Stimulating Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor patients using this combination for signs and symptoms of thromboembolism such as swelling, redness, warmth, or pain in the legs, dyspnea, tachypnea, hemoptysis, or chest pain. Advise patients of potential risks and encourage prompt reporting of any thromboembolism signs or symptoms.</p>\n<div>\n <p><b>Erythropoiesis-Stimulating Agents Interacting Members</b> Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin Lambda, Epoetin Zeta, Methoxy Polyethylene Glycol-Epoetin Beta</p>\n</div> \n<p><b>Discussion</b> Lenalidomide prescribing information warns of a possible increase in the risk for thromboembolism with concomitant use of drugs that may independently increase the risk for thromboembolism, such as erythropoiesis-stimulating agents or estrogen-containing therapies, though specific data regarding the actual risks with such combinations are lacking.<sup>1</sup> The use of lenalidomide itself is associated with a significant risk for thromboembolism; as described in the prescribing information, 11% of those treated with thalidomide plus dexamethasone experienced thromboembolism versus 4% of those treated with dexamethasone alone in a study of patients with multiple myeloma.<sup>1</sup><br><br>Use of the erythropoiesis-stimulating agents is also associated with a significant risk for death, myocardial infarction, stroke, and other thromboembolic events.<sup>2,3,4,5</sup><br><br>The proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Revlimid</i> (lenalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; September 2014.</p>\n<p>2. <i>Aranesp</i> (darbepoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2013.</p>\n<p>3. <i>Epogen</i> (epoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2013.</p>\n<p>4. <i>Mircera</i> (methoxy polyethylene glycol-epoetin beta) [prescribing information]. South San Francisco, CA: Hoffmann-La Roche Inc; October 2014.</p>\n<p>5. <i>Neorecormon</i> (epoetin beta) [summary of product characteristics]. Welwyn Garden City, Hertfordshire, United Kingdom: Roche Products Limited; October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8780":"<p><b>Title</b> Erythropoiesis-Stimulating Agents / Nandrolone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nandrolone may enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for elevations in hemoglobin and/or hematocrit and the need for decreased erythropoiesis-stimulating agent requirements if combined with nandrolone.</p>\n<div>\n <p><b>Erythropoiesis-Stimulating Agents Interacting Members</b> Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin Lambda, Epoetin Zeta, Methoxy Polyethylene Glycol-Epoetin Beta</p>\n</div> \n<p><b>Discussion</b> Product labeling for nandrolone states that the combination of nandrolone and an erythropoiesis-stimulating agent (ESA) may require a reduction in the dose of the ESA product.<sup>1,2</sup><br><br>In two trials, patients who received an ESA plus nandrolone had a greater increase in hematocrit levels compared to patients who received an ESA alone.<sup>3,4</sup>. One study found that an ESA plus nandrolone increased hemoglobin and hematocrit levels greater than an ESA alone in females, but not in males.<sup>5</sup> In contrast, two other studies found that the addition of nandrolone did not enhance the response rate to the ESA.<sup>6,7</sup> <br><br>The mechanism by which nandrolone may alleviate anemia and thus reduce ESA requirements is not completely understood. It has been postulated that nandrolone may increase sensitivity to erythroid progenitors or increase endogenous erythropoietin production.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Deca Durabolin</i> (nandrolone) [summary of product characteristics]. South Granville, NSW, Australia: Merck Sharp &amp; Dohme (Australia) Pty Limited; July 2013. </p>\n<p>2. <i>Deca-Durabolin</i> (nandrolone) [summary of product characteristics] Oss, The Netherlands: N.V. Organon; July 2012.</p>\n<p>3. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. <i>Am J Kidney Dis</i>. 1991;17(1):29-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1986567\">[PubMed 1986567]</a></p>\n<p>4. Gaughan WJ, Liss KA, Dunn SR, et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. <i>Am J Kidney Dis</i>. 1997;30(4):495-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9328363\">[PubMed 9328363]</a></p>\n<p>5. Lee MS, Ahn SH, Song JH. Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin. <i>Korean J Intern Med</i>. 2002;17(3):167-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12298427\">[PubMed 12298427]</a></p>\n<p>6. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. <i>Clin Nephrol</i>. 1992;37(5):264-267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1606777\">[PubMed 1606777]</a></p>\n<p>7. Sheashaa H, Abdel-Razek W, El-Husseini A, et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. <i>Nephron Clin Pract</i>. 2005;99(4):c102-c106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15703460\">[PubMed 15703460]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8781":"<p><b>Title</b> Imidapril / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Imidapril. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased antihypertensive effect of imidapril if rifampin therapy is initiated. Conversely, monitor for exaggerated hypotensive response if rifampin therapy is discontinued in a patient taking imidapril.</p> \n<p><b>Discussion</b> Product labeling for imidapril states that the administration of rifampin resulted in reduced plasma levels of imidaprilat (the active metabolite of imidapril), which may reduce the antihypertensive effect of imidapril.<sup>1</sup> No details regarding study design or the magnitude of change in imidaprilat exposure are provided.<br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tanatril</i> (imidapril) [summary of product characteristics]. London, UK: Mitsubishi Tanabe Pharma Europe Limited; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8782":"<p><b>Title</b> Dexketoprofen / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Dexketoprofen. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for possible dexketoprofen-related toxicity if coadministered with probenecid. The dexketoprofen summary of product characteristics cautions that use of this combination will require dexketoprofen dose adjustment, but specific dose adjustment recommendations are not provided.</p> \n<p><b>Discussion</b> The AUC of dexketoprofen (S-ketoprofen) was increased by an average of 2.5-fold in a study of 5 healthy subjects who received racemic ketoprofen (50 mg) with probenecid (1 g).<sup>1</sup> The AUC of R-ketoprofen was increased by an average of 2-fold. The clearance of ketoprofen (50 mg every 6 hours) was similarly decreased by an average of 67% in 6 healthy subjects when administered with probenecid (500 mg every 6 hours).<sup>2</sup> Data from a study in rats also show increased ketoprofen concentrations with increasing probenecid concentrations.<sup>3</sup> The dexketoprofen summary of product characteristics cautions that use of this combination may result in increased dexketoprofen concentrations and will require dexketoprofen dose adjustment, but specific dose adjustment recommendations are not provided.<sup>4,5,6</sup><br><br>The precise mechanism of this interaction is unclear. Probenecid has been proposed to inhibit the renal secretion and/or glucuronidation of ketoprofen.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Foster RT, Jamali F, Russell AS. Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid. <i>Eur J Clin Pharmacol</i>. 1989;37(6):589-594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2612555\">[PubMed 2612555]</a></p>\n<p>2. Upton RA, Williams RL, Buskin JN, Jones RM. Effects of probenecid on ketoprofen kinetics. <i>Clin Pharmacol Ther</i>. 1982;31(6):705-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7075118\">[PubMed 7075118]</a></p>\n<p>3. Palylyk EL, Jamali F. Ketoprofen-probenecid interaction in the rat: a probenecid concentration-dependent stereoselective process. <i>J Pharm Sci</i>. 1993;82(3):296-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8450425\">[PubMed 8450425]</a></p>\n<p>4. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>5. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>6. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8783":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dexketoprofen may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of dexketoprofen with any other nonsteroidal antiinflammatory agents should be avoided.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The dexketoprofen summary of product characteristics cautions that use of dexketoprofen together with any other nonsteroidal antiinflammatory agent should be avoided due to a possible increased risk for gastrointestinal ulcers and bleeding.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8784":"<p><b>Title</b> Verteporfin / Photosensitizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for evidence of enhanced photosensitivity when verteporfin is used with other photosensitizing agents.</p>\n<div>\n <p><b>Photosensitizing Agents Interacting Members</b> Aceclofenac, Acemetacin, Acitretin, Adapalene, Afatinib, Afloqualone, Alitretinoin (Systemic), Alitretinoin (Topical), Aminolevulinic Acid (Systemic), Aminolevulinic Acid (Topical), Amiodarone, Bendroflumethiazide, Bexarotene (Systemic), Bexarotene (Topical), Bicalutamide, Calcitriol (Topical), Celecoxib, Chlorothiazide, ChlorproMAZINE, ChlorproPAMIDE, Chlorthalidone, Ciprofloxacin (Systemic), Cobimetinib, Cyclopenthiazide, Demeclocycline, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Dong Quai, Doxycycline, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, FluPHENAZine, Flurbiprofen (Systemic), Gemifloxacin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Griseofulvin, HydroCHLOROthiazide, Hydroflumethiazide, Ibuprofen, Ibuprofen (Topical), Indapamide, Indomethacin, ISOtretinoin (Systemic), Isotretinoin (Topical), Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Lornoxicam, Loxoprofen, Lymecycline, Meclofenamate, Mefenamic Acid, Meloxicam, Methotrimeprazine, Methyclothiazide, MetOLazone, Minocycline, Morniflumate, Moxifloxacin (Systemic), Nabumetone, Nadifloxacin, Nalidixic Acid, Naproxen, Nimesulide, Norfloxacin, Ofloxacin (Systemic), Oxaprozin, Oxytetracycline, Panitumumab, Parecoxib, Pelubiprofen, Periciazine, Perphenazine, Phenylbutazone, Pipemidic Acid, Pipotiazine, Pirfenidone, Piroxicam (Systemic), Piroxicam (Topical), Porfimer, Prochlorperazine, Promazine, Propyphenazone, Simeprevir, Sparfloxacin, St John's Wort, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Sulindac, Talniflumate, Tenoxicam, Tetracycline (Systemic), Thioridazine, Tiaprofenic Acid, TOLAZamide, TOLBUTamide, Tolfenamic Acid, Tolmetin, Tretinoin (Systemic), Tretinoin (Topical), Trifluoperazine, Vemurafenib, Verteporfin, Voriconazole, Xipamide, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Verteporfin prescribing information cautions that concurrent use with other photosensitizing agents may increase the risk for a photosensitivity reaction.<sup>1</sup> The individual drugs listed herein as being photosensitizing agents are included primarily based on the findings of published analyses/reviews and individual drug labeling information.<sup>2,3,4</sup><br><br>The proposed mechanism for this potential interaction is additive phototoxicity between verteporfin and other photosensitizing agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Visudyne</i> (verteporfin) [prescribing information]. Rochester, MI: JHP Pharmaceuticals LLC; June 2012.</p>\n<p>2. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. <i>Br J Clin Pharmacol</i>. 1999;48(6):839-846. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594488\">[PubMed 10594488]</a></p>\n<p>3. Lankerani L, Baron ED. Photosensitivity to exogenous agents. <i>J Cutan Med Surg</i>. 2004;8(6):424-431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15988550\">[PubMed 15988550]</a></p>\n<p>4. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. <i>Drug Saf</i>. 2011;34(10):821-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21879777\">[PubMed 21879777]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8785":"<p><b>Title</b> Lenalidomide / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor patients using this combination for signs and symptoms of thromboembolism such as swelling, redness, warmth, or pain in the legs, dyspnea, tachypnea, hemoptysis, or chest pain. Advise patients of potential risks and encourage prompt reporting of any thromboembolism signs or symptoms.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> Lenalidomide prescribing information warns of a possible increase in the risk for thromboembolism with concomitant use of drugs that may independently increase the risk for thromboembolism, such as erythropoiesis-stimulating agents or estrogen-containing therapies, although specific data regarding the actual risks with such combinations are lacking.<sup>1</sup> The use of lenalidomide itself is associated with a significant risk for thromboembolism; as described in the prescribing information, 11% of those treated with thalidomide plus dexamethasone experienced thromboembolism versus 4% of those treated with dexamethasone alone in a study of patients with multiple myeloma.<sup>1</sup><br><br>The proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Revlimid</i> (lenalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8786":"<p><b>Title</b> MiFEPRIStone / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexketoprofen may diminish the therapeutic effect of MiFEPRIStone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The dexketoprofen summary of product characteristics cautions that nonsteroidal antiinflammatory drugs (NSAIDs), such as dexketoprofen, should not be used for 8 to 12 days after mifepristone administration. Several clinical studies of such combinations have not found any evidence of such an interaction. Carefully consider the appropriateness of using such a combination, and when suitable alternatives exist, consider avoiding concurrent use to minimize any potential for an interaction.</p> \n<p><b>Discussion</b> The dexketoprofen summary of product characteristics cautions that nonsteroidal antiinflammatory drugs (NSAIDs), such as dexketoprofen, should not be used for 8 to 12 days after mifepristone administration due to a possible risk for interference with mifepristone actions.<sup>1,2,3</sup> One study reported evidence of a decrease in some mifepristone-related prostaglandin production associated with indomethacin treatment but noted that the effects of mifepristone on uterine activity were not altered by indomethacin.<sup>4</sup> Several other clinical studies have reported that use of NSAIDs had no impact on the effectiveness of mifepristone,<sup>5,6,7,8,9</sup> calling into question the true clinical significance of this possible interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>4. Norman JE, Kelly RW, Baird DT. Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in vivo. <i>Hum Reprod</i>. 1991;6(5):740-744. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1939561\">[PubMed 1939561]</a></p>\n<p>5. Raymond EG, Weaver MA, Louie KS, et al. Prophylactic compared with therapeutic ibuprofen analgesia in first-trimester medical abortion: a randomized controlled trial. <i>Obstet Gynecol</i>. 2013;122(3):558-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23921857\">[PubMed 23921857]</a></p>\n<p>6. Avraham S, Gat I, Duvdevani NR, Haas J, Frenkel Y, Seidman DS. Pre-emptive effect of ibuprofen versus placebo on pain relief and success rates of medical abortion: a double-blind, randomized, controlled study. <i>Fertil Steril</i>. 2012;97(3):612-615. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22265034\">[PubMed 22265034]</a></p>\n<p>7. Livshits A, Machtinger R, David LB, Spira M, Moshe-Zahav A, Seidman DS. Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study. <i>Fertil Steril</i>. 2009;91(5):1877-1880. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18359021\">[PubMed 18359021]</a></p>\n<p>8. Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. <i>Hum Reprod</i>. 2005;20(11):3072-3077. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16055455\">[PubMed 16055455]</a></p>\n<p>9. Radestad A, Bygdeman M. Cervical softening with mifepristone (RU 486) after pretreatment with naproxen. A double-blind randomized study. <i>Contraception</i>. 1992;45(3):221-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1511608\">[PubMed 1511608]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8787":"<p><b>Title</b> Zidovudine / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexketoprofen may enhance the adverse/toxic effect of Zidovudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The dexketoprofen summary of product characteristics recommends obtaining a complete blood count and reticulocyte count at 1-2 weeks following use of this combination in order to monitor for the development of anemia or other red blood cell toxicities, which are reportedly most likely approximately 1 week after starting the combination.</p> \n<p><b>Discussion</b> The dexketoprofen summary of product characteristics recommends obtaining a complete blood count and reticulocyte count at 1-2 weeks following use of this combination in order to monitor for the development of anemia or other red blood cell toxicities, which are reportedly most likely approximately 1 week after starting the combination.<sup>1,2,3</sup> Though no published studies specifically address a possible risk for anemia or other red blood cell toxicities with this combination, there is evidence that several nonsteroidal antiinflammatory drugs (NSAIDs), such as dexketoprofen, may impair zidovudine metabolism and/or transport and may increase intracellular zidovudine concentrations from both clinical studies<sup>4</sup> and animal studies.<sup>5,6,7,8</sup> In contrast, other clinical and animal studies have reported no significant change in zidovudine pharmacokinetics with concurrent administration of NSAIDs.<sup>9,10,11</sup><br><br>The specific mechanism for any possible interaction is uncertain, but NSAID inhibition of zidovudine glucuronidation and/or efflux via multidrug resistance protein 4 (MRP4) are possible explanations.<sup>5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>4. Barry M, Howe J, Back D, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. <i>Br J Clin Pharmacol</i>. 1993;36(1):82-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8373716\">[PubMed 8373716]</a></p>\n<p>5. Clemente MI, Alvarez S, Serramia MJ, et al. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. <i>Antivir Ther</i>. 2009;14(8):1101-1111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20032540\">[PubMed 20032540]</a></p>\n<p>6. Mano Y, Usui T, Kamimura H. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. <i>Drug Metab Dispos</i>. 2007;35(4):602-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267620\">[PubMed 17267620]</a></p>\n<p>7. Mano Y, Usui T, Kamimura H. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2007;63(2):211-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17200831\">[PubMed 17200831]</a></p>\n<p>8. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. <i>Br J Clin Pharmacol</i>. 1991;32(1):17-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1909542\">[PubMed 1909542]</a></p>\n<p>9. Sahai J, Gallicano K, Garber G, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. <i>Clin Pharmacol Ther</i>. 1992;52(5):464-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1424420\">[PubMed 1424420]</a></p>\n<p>10. Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. <i>Am J Hematol</i>. 1992;40(3):176-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1609771\">[PubMed 1609771]</a></p>\n<p>11. Radwan MA. Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. <i>J Pharm Pharmacol</i>. 2000;52(6):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10875543\">[PubMed 10875543]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8788":"<p><b>Title</b> Immune Globulin / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for signs and symptoms of thrombosis if an immune globulin is combined with an estrogen derivative. Consider administration of the immune globulin at the minimum dose and slowest infusion rate practical to minimize thrombosis risk.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> Product labeling in the US and Canada contains a boxed warning describing the risk of thrombosis with immune globulin therapy and a possible increase in the risk for thromboembolism with concomitant use of estrogen derivatives.<sup>1,2,3,4,5</sup> Specific data regarding the actual risks with such combinations are lacking, but one case report suggests that the combination of immune globulin and estrogen (and possibly other risk factors) contributed to a fatal thromboembolic event in a 13-year-old patient.<sup>6</sup> The manufacturers suggest using the most practical minimum dose and slowest infusion rate when immune globulin is combined with estrogen derivatives and to monitor patients closely for signs and symptoms of thrombosis.<br><br>Since both agents have been reported to independently increase thrombosis risk, the proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Carimune</i> (immune globulin) [prescribing information]. Kankakee, IL: CSL Behring LLC; August 2013.</p>\n<p>2. <i>Bivigam</i> (immune globulin) [prescribing information]. Boca Raton, FL: Biotest Pharmaceuticals Corporation; June 2013.</p>\n<p>3. <i>Flebogamma DIF</i> (immune globulin) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; September 2013.</p>\n<p>4. <i>Gammagard S/D</i> (immune globulin) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corportation; September 2013.</p>\n<p>5. <i>Gammagard Liquid</i> (immune globulin) [product monograph]. Mississauga, Ontario, Canada: Baxter Corporation; September 2014.</p>\n<p>6. Iroh Tam PY, Richarson M, Grewal S. Fatal case of bilateral internal jugular vein thrombosis following IVIg infusion in an adolescent girl treated for ITP. <i>Am J Hematol</i> 2008;83(4):323-325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17975805\">[PubMed 17975805]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8789":"<p><b>Title</b> Fosphenytoin-Phenytoin / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexketoprofen may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of phenytoin toxicity if using this combination. Due to possible protein binding displacement total phenytoin concentrations may not be representative of active (i.e., free or unbound) phenytoin concentrations. The dexketoprofen summary of product characteristics describes concomitant use of a hydantoin (e.g., phenytoin, dantrolene) as inadvisable due to risk for increased hydantoin toxicity.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> The dexketoprofen summary of product characteristics describes concomitant use of a hydantoin (e.g., phenytoin, dantrolene) as inadvisable due to risk for increased hydantoin toxicity.<sup>1,2,3</sup> Though no published studies specifically address such particular combinations, studies and case reports with the nonsteroidal antiinflammatory drugs (NSAIDs) azapropazone, bromfenac, ibuprofen, and aspirin have reported increases in phenytoin concentrations (free or total) and/or toxicities.<sup>4,5,6,7,8,9,10,11,12</sup> Of note, many of these reports describe the observed pharmacokinetic interaction as relatively small and likely of little clinical significance beyond a lessened ability to rely on total phenytoin concentrations for guiding therapy decisions (due to protein binding displacement).<sup>7,8,9,10,11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>4. Geaney DP, Carver JG, Davies CL, Aronson JK. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. <i>Br J Clin Pharmacol</i>. 1983;15(6):727-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6871071\">[PubMed 6871071]</a></p>\n<p>5. Sandyk R. Phenytoin toxicity induced by interaction with ibuprofen. <i>S Afr Med J</i>. 1982;62(17):592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7123429\">[PubMed 7123429]</a></p>\n<p>6. Geaney DP, Carver JG, Aronson JK, Warlow CP. Interaction of azapropazone with phenytoin. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6326):1373. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6803981\">[PubMed 6803981]</a></p>\n<p>7. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM. Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males. <i>J Clin Pharmacol</i>. 1997;37(2):160-168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9055143\">[PubMed 9055143]</a></p>\n<p>8. Bachmann KA, Schwartz JI, Forney RB Jr, Jauregui L, Sullivan TJ. Inability of ibuprofen to alter single dose phenytoin disposition. <i>Br J Clin Pharmacol</i>. 1986;21(2):165-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3954932\">[PubMed 3954932]</a></p>\n<p>9. Olanow CW, Finn AL, Prussak C. The effects of salicylate on the pharmacokinetics of phenytoin. <i>Neurology</i>. 1981;31(3):341-342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7193826\">[PubMed 7193826]</a></p>\n<p>10. Leonard RF, Knott PJ, Rankin GO, Robinson DS, Melnick DE. Phenytoin-salicylate interaction. <i>Clin Pharmacol Ther</i>. 1981;29(1):56-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7460475\">[PubMed 7460475]</a></p>\n<p>11. Paxton JW. Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. <i>Clin Pharmacol Ther</i>. 1980;27(2):170-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353335\">[PubMed 7353335]</a></p>\n<p>12. Fraser DG, Ludden TM, Evens RP, Sutherland EW 3rd. Displacement of phenytoin from plasma binding sites by salicylate. <i>Clin Pharmacol Ther</i>. 1980;27(2):165-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353334\">[PubMed 7353334]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8790":"<p><b>Title</b> Dantrolene / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexketoprofen may enhance the adverse/toxic effect of Dantrolene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of dantrolene toxicity if using this combination. The dexketoprofen summary of product characteristics describes concomitant use of a hydantoin (e.g., phenytoin, dantrolene) as inadvisable due to risk for increased hydantoin toxicity.</p> \n<p><b>Discussion</b> The dexketoprofen summary of product characteristics describes concomitant use of a hydantoin (e.g., phenytoin, dantrolene) as inadvisable due to risk for increased hydantoin toxicity.<sup>1,2,3</sup> Though no published studies specifically address such particular combinations, studies and case reports with the nonsteroidal antiinflammatory drugs (NSAIDs) azapropazone, bromfenac, ibuprofen, and aspirin have reported increases in phenytoin concentrations (free or total) and/or toxicities.<sup>4,5,6,7,8,9,10,11,12</sup> Of note, many of these reports describe the observed pharmacokinetic interaction as relatively small and likely of little clinical significance beyond a lessened ability to rely on total phenytoin concentrations for guiding therapy decisions (due to protein binding displacement).<sup>7,8,9,10,11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>4. Geaney DP, Carver JG, Davies CL, Aronson JK. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. <i>Br J Clin Pharmacol</i>. 1983;15(6):727-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6871071\">[PubMed 6871071]</a></p>\n<p>5. Sandyk R. Phenytoin toxicity induced by interaction with ibuprofen. <i>S Afr Med J</i>. 1982;62(17):592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7123429\">[PubMed 7123429]</a></p>\n<p>6. Geaney DP, Carver JG, Aronson JK, Warlow CP. Interaction of azapropazone with phenytoin. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6326):1373. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6803981\">[PubMed 6803981]</a></p>\n<p>7. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM. Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males. <i>J Clin Pharmacol</i>. 1997;37(2):160-168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9055143\">[PubMed 9055143]</a></p>\n<p>8. Bachmann KA, Schwartz JI, Forney RB Jr, Jauregui L, Sullivan TJ. Inability of ibuprofen to alter single dose phenytoin disposition. <i>Br J Clin Pharmacol</i>. 1986;21(2):165-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3954932\">[PubMed 3954932]</a></p>\n<p>9. Olanow CW, Finn AL, Prussak C. The effects of salicylate on the pharmacokinetics of phenytoin. <i>Neurology</i>. 1981;31(3):341-342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7193826\">[PubMed 7193826]</a></p>\n<p>10. Leonard RF, Knott PJ, Rankin GO, Robinson DS, Melnick DE. Phenytoin-salicylate interaction. <i>Clin Pharmacol Ther</i>. 1981;29(1):56-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7460475\">[PubMed 7460475]</a></p>\n<p>11. Paxton JW. Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. <i>Clin Pharmacol Ther</i>. 1980;27(2):170-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353335\">[PubMed 7353335]</a></p>\n<p>12. Fraser DG, Ludden TM, Evens RP, Sutherland EW 3rd. Displacement of phenytoin from plasma binding sites by salicylate. <i>Clin Pharmacol Ther</i>. 1980;27(2):165-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353334\">[PubMed 7353334]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8791":"<p><b>Title</b> Sulfonamides / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexketoprofen may enhance the adverse/toxic effect of Sulfonamides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of sulfonamide-related toxicity if using this combination. The dexketoprofen summary of product characteristics describes concomitant use of a sulfonamide as inadvisable due to risk for increased sulfonamide toxicity.</p>\n<div>\n <p><b>Sulfonamides Interacting Members</b> AcetaZOLAMIDE, Bendroflumethiazide, Bumetanide, Celecoxib, Chlorothiazide, ChlorproPAMIDE, Chlorthalidone, Cyclopenthiazide, Furosemide, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Nimesulide, Parecoxib, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, Sulfanilamide, SulfiSOXAZOLE, Sulthiame, TOLAZamide, TOLBUTamide, Torsemide, Xipamide</p>\n</div> \n<p><b>Discussion</b> The dexketoprofen summary of product characteristics describes concomitant use of a sulfonamide as inadvisable due to risk for increased sulfonamide toxicity.<sup>1,2,3</sup> No published studies or reports specifically addressing such concerns could be identified.<br><br>The specific mechanism for any such interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8792":"<p><b>Title</b> Elvitegravir / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of efavirenz with elvitegravir is not recommended due to a possible decrease in elvitegravir concentrations, which could lead to a loss of effectiveness and/or an increased risk for development of resistance.</p> \n<p><b>Discussion</b> Guidelines for use of antiretroviral agents in HIV-infected patients recommend avoiding concurrent use of elvitegravir with efavirenz due to the potential for significant changes in elvitegravir concentrations.<sup>1</sup> The prescribing information for elvitegravir also recommends avoiding this combination due to risk for decreased elvitegravir concentrations, which could lead to a loss of effectiveness and/or an increased risk for development of resistance.<sup>2</sup><br><br>The likely mechanism for this potential interaction is efavirenz-mediated induction in the CYP3A metabolism of elvitegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Published May 2014. Accessed October 2014.</p>\n<p>2. <i>Vitekta</i> (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8793":"<p><b>Title</b> Elvitegravir / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of nevirapine with elvitegravir is not recommended due to a possible decrease in elvitegravir concentrations, which could lead to a loss of effectiveness and/or an increased risk for development of resistance.</p> \n<p><b>Discussion</b> Guidelines for use of antiretroviral agents in HIV-infected patients recommends avoiding concurrent use of elvitegravir with nevirapine due to the potential for significant changes in elvitegravir concentrations.<sup>1</sup> The prescribing information for elvitegravir also recommends avoiding this combination due to risk for decreased elvitegravir concentrations, which could lead to a loss of effectiveness and/or an increased risk for development of resistance.<sup>2</sup><br><br>The likely mechanism for this potential interaction is nevirapine-mediated induction in the CYP3A metabolism of elvitegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Published May 2014. Accessed October 2014.</p>\n<p>2. <i>Vitekta</i> (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8794":"<p><b>Title</b> Netupitant / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Netupitant. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. Exposure to netupitant is increased in the presence of strong CYP3A4 inhibitors. However, because one-time dosing is the only approved regimen (as opposed to multi-dose use) of the netupitant/palonosetron combination product, no dose adjustment or increased monitoring is recommended.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 36 healthy volunteers, netupitant (administered as a single dose of the combination product netupitant 300 mg and palonosetron 0.5 mg) AUC increased 140% and the maximum serum concentration (Cmax) increased 25% when given on day 4 of a 12-day course of ketoconazole (400 mg daily).<sup>1,2</sup> <br><br>Prescribing information for the netupitant/palonosetron combination product states that the exposure of netupitant is significantly higher when coadministered with strong CYP3A4 inhibitors (eg, ketoconazole), but dosage adjustment is not necessary for single dose administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. <i>Support Care Cancer</i>. 2013;21(10):2879-2887. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23748441\">[PubMed 23748441]</a></p>\n<p>2. <i>Akynzeo</i> (netupitant and palonosetron) [prescribing information]. Somerset, NJ: Catalent Pharma Solutions; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8795":"<p><b>Title</b> Netupitant / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of netupitant with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 36 healthy volunteers, netupitant (administered as a single dose of the combination product netupitant 300 mg and palonosetron 0.5 mg) AUC decreased 83% and the maximum serum concentration (Cmax) decreased 62% when given on day 9 of a 17-day course of rifampin (600 mg daily).<sup>1,2</sup> <br><br>Prescribing information for the netupitant/palonosetron combination product states that the exposure of netupitant is significantly lower when coadministered with strong CYP3A4 inducers (eg, rifampin) and that concomitant use should be avoided.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. <i>Support Care Cancer</i>. 2013;21(10):2879-2887. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23748441\">[PubMed 23748441]</a></p>\n<p>2. <i>Akynzeo</i> (netupitant and palonosetron) [prescribing information]. Somerset, NJ: Catalent Pharma Solutions; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8796":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Netupitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Netupitant may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of CYP3A4 substrates (decreased effects for prodrugs activated by CYP3A4) when netupitant is coadministered with a CYP3A4 substrate. Due to the long half-life of netupitant, the inhibitory effect on CYP3A4 may last for multiple days.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, netupitant (300 mg single dose) increased the sensitive CYP3A4 substrate midazolam (7.5 mg single oral dose) AUC by 126% and the maximum serum concentration (Cmax) increased 36% in 10 healthy volunteers.<sup>1</sup> <br><br>Although changes in exposure were less than that seen with midazolam, increases in other CYP3A4 substrates have also been reported when combined with netupitant. Netupitant (300 mg single dose) increased the erythromycin (500 mg single dose) AUC and Cmax by 56% and 92%, respectively in healthy volunteers.<sup>1,2</sup> In cancer patients, docetaxel AUC and Cmax increased 35% and 49%, etoposide AUC and Cmax increased 28% and 10%, and cyclophosphamide AUC and Cmax increased 20% and 27%, respectively, with administration of the netupitant/palonosetron combination product compared with use of palonosetron alone.<sup>2</sup> <br><br>Product labeling for the netupitant/palonosetron combination product warns that concomitant use with medications primarily metabolized via CYP3A4 may result in increased exposure to the CYP3A4 substrate. Increased monitoring for increases in plasma concentrations and/or toxicity of CYP3A4 substrates is recommended if combined with netupitant.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lanzarotti C, Rossi G. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. <i>Support Care Cancer</i>. 2013;21(10):2783-2791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23729226\">[PubMed 23729226]</a></p>\n<p>2. <i>Akynzeo</i> (netupitant and palonosetron) [prescribing information]. Somerset, NJ: Catalent Pharma Solutions; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8797":"<p><b>Title</b> Dexamethasone (Systemic) / Netupitant</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Netupitant may increase the serum concentration of Dexamethasone (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Decrease dexamethasone doses to 12 mg on day 1 and, if needed based on the emetic potential of the regimen, to 8 mg daily on days 2 to 4 of chemotherapy when administered with netupitant. The dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with the netupitant/palonosetron combination product reflect this dose decrease.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 19 healthy volunteers, netupitant (single dose of 100 mg, 300 mg, or 450 mg) increased the exposure to dexamethasone (20 mg on day 1, 8 mg twice daily on days 2 to 4) in a dose- and time-dependent manner.<sup>1,2</sup> With coadministration of 100 mg, 300 mg, or 450 mg of netupitant, the dexamethasone AUC on day 1 increased 48%, 72%, and 75%, respectively. The AUC on day 2 increased 109%, 143%, and 158%, respectively, and the AUC on day 4 increased 75%, 140%, and 170%, respectively.<sup>1,2</sup><br><br>Due to the increases in dexamethasone exposure when administered with netupitant, prescribing information for the netupitant/palonosetron combination product recommends administering dexamethasone at a reduced dose of 12 mg on day 1 and, if needed based on the emetic potential of the chemotherapy regimen, to 8 mg once daily on days 2 to 4.<sup>2</sup> This reduced dexamethasone dosing regimen was used in clinical chemotherapy nausea/vomiting trials evaluating the netupitant/palonosetron combination product.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lanzarotti C, Rossi G. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. <i>Support Care Cancer</i>. 2013;21(10):2783-2791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23729226\">[PubMed 23729226]</a></p>\n<p>2. <i>Akynzeo</i> (netupitant and palonosetron) [prescribing information]. Somerset, NJ: Catalent Pharma Solutions; October 2014.</p>\n<p>3. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. <i>Ann Oncol</i>. 2014;25(7):1333-1339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24631949\">[PubMed 24631949]</a></p>\n<p>4. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. <i>Ann Oncol</i>. 2014;25(7):1328-1333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24603643\">[PubMed 24603643]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8798":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Peginterferon Alfa-2b</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Peginterferon Alfa-2b may decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to CYP2D6 substrates when used with peginterferon alfa-2b.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In a clinical study of patients with hepatitis C, treatment with peginterferon alfa-2b (1.5 mcg/kg weekly for 4 weeks) was associated with an average 66% increase in CYP2D6 activity (estimated using dextromethorphan metabolism).<sup>1</sup> This effect was highly variable, with 13 subjects (59%) demonstrating an increase in CYP2D6 activity, but 5 (23%) subjects and 4 (18%) subjects demonstrating either a decrease or no change, respectively, in CYP2D6 activity. In a clinical studies of patients with hepatitis C described in the peginterferon alfa-2b prescribing information, peginterferon alfa-2b (1.5 mcg/kg weekly for 4 weeks) did not affect the AUC of dextromethorphan.<sup>2</sup> In a study of healthy volunteers, peginterferon alfa-2b (1 mcg/kg weekly for 4 weeks) increased the dextromethorphan AUC 2-fold.<sup>2</sup> In another study of healthy volunteers, peginterferon alfa-2b (3 mcg/kg weekly for 2 weeks) increased the desipramine AUC 30%.<sup>2</sup> <br><br>The mechanisms of these interactions are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. <i>Eur J Clin Pharmacol</i>. 2011;67(6):591-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21161196\">[PubMed 21161196]</a></p>\n<p>2. PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8799":"<p><b>Title</b> Ledipasvir / P-glycoprotein/ABCB1 Inducers</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and a P-glycoprotein inducer.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>Prescribing information for the ledipasvir/sofosbuvir combination product warns that concomitant use of ledipasvir and P-glycoprotein inducers (eg, rifampin) may lead to a reduced therapeutic effect and should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}